PrettyNiuNiu personal page - To The Moon

PrettyNiuNiu

PrettyNiuNiu

No personal profile

69Follow

6Followers

0Topic

0Badge

2021-06-18

Feat

Alibaba Stock: The Bottoming Process Looks To Be Forming Already

2021-06-11

Likes

2021-06-10

Lnc

Sorry, the original content has been removed

2021-06-04

Woo

Here's AMC's blunt new warning to prospective buyers of its new stock offering

2021-06-01

Tesla

Sorry, the original content has been removed

2021-06-01

Tesla

Sorry, the original content has been removed

2021-06-01

Comment

Sorry, the original content has been removed

2021-06-01

Like & comm

Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

2021-06-01

Like and comment

Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

2021-06-01

Like & comm

Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

2021-05-25

Like & comm

Sorry, the original content has been removed

2021-05-25

Hmm

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3584575502696721","uuid":"3584575502696721","gmtCreate":1621482187187,"gmtModify":1624160863700,"name":"PrettyNiuNiu","pinyin":"prettyniuniu","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":69,"tweetSize":12,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":168556210,"gmtCreate":1623979283330,"gmtModify":1703825296747,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Feat","listText":"Feat","text":"Feat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":14,"repostSize":0,"link":"https://ttm.financial/post/168556210","repostId":"1175693382","repostType":4,"repost":{"id":"1175693382","pubTimestamp":1623978463,"share":"https://ttm.financial/m/news/1175693382?lang=&edition=fundamental","pubTime":"2021-06-18 09:07","market":"hk","language":"en","title":"Alibaba Stock: The Bottoming Process Looks To Be Forming Already","url":"https://stock-news.laohu8.com/highlight/detail?id=1175693382","media":"seekingalpha","summary":"Alibaba is probably the most undervalued growth stock right now.The company’s multiple growth drivers within a rapidly expanding market made its valuations look even more baffling.The short term technical picture may be turning bullish with a potential double bottom price action signal.When we take things into clearer perspective by comparing China’s growth rate and size of its market to that of the U.S. e-commerce market, we could see the huge differences in their sizes and growth rates as the ","content":"<p><b>Summary</b></p>\n<ul>\n <li>Alibaba is probably the most undervalued growth stock right now.</li>\n <li>The company’s multiple growth drivers within a rapidly expanding market made its valuations look even more baffling.</li>\n <li>The short term technical picture may be turning bullish with a potential double bottom price action signal.</li>\n <li>We discuss the company’s multiple growth drivers and let investors judge for themselves.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/05e63c77d4f3f3dc3d618e43044638bb\" tg-width=\"768\" tg-height=\"512\"><span>Yongyuan Dai/iStock Unreleased via Getty Images</span></p>\n<p><b>The Technical Thesis</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7febf6ed056b0e3bc038321cdaad9b1c\" tg-width=\"1280\" tg-height=\"782\"><span>Source: TradingView</span></p>\n<p>Alibaba’s&nbsp;stock price has endured a terrible 8 months ever since its Ant Financial IPO was pulled in early Nov 20, with the stock languishing in the doldrums 34% off its high. When considering the health of its long term uptrend, it’s clear that BABA has a relatively strong uptrend bias and has generally been well supported along its key 50W MA. The only other time in the last 4 years that it lost its key 50W MA support level was during the 2018 bear market where BABA dropped about 40%, but was still well supported above the important 200W MA, which we usually consider as the “last line of defense”. Right now BABA is somewhat facing a similar situation again: down 34%, lost the 50W MA, but looks to be well supported above the 200W MA. In addition to that, one interesting observation in price action analysis may lead price action traders/investors to be especially bullish: a potential double bottom formation. BABA's price is seemingly going through a double bottom like it did during the 2018 bear market before it rallied strongly thereafter. As a result, BABA’s current level may offer a possible technical buy entry point now.</p>\n<p><b>BABA's Fundamental Thesis: Rapidly Expanding Growth Drivers</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eba49f5881708929949c30628eedc5d4\" tg-width=\"934\" tg-height=\"578\"><span>Annual GMV. Data source: Company filings</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a4d6c4ed3e2402f5af52b2dea8bab411\" tg-width=\"836\" tg-height=\"517\"><span>Annual e-commerce revenue. Data source: Company filings</span></p>\n<p>BABA’s GMV grew from 1.68T yuan to 7.49T yuan in just a matter of 7 years, which represented a CAGR of 23.8%, a truly amazing growth rate. We also saw its GMV growth being converted into revenue growth as its China commerce revenue grew from 7.67B yuan to 473.68B yuan, at a CAGR of 51% over the last 10 years. While its international footprint remains considerably smaller, it still grew at a CAGR of 30.42% over the last 10 years, which was by no means slow.</p>\n<p>Even though China’s e-commerce market is expected to grow considerably slower at a CAGR of 12.4% over the next three years, from 13.8T yuan, equivalent to $2.16T in 2021 to 19.6T yuan,equivalent to $3.06T by 2024, the massive size of the market still offers tremendous upside potential for BABA and its closest competitors to grow into.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ffe2dee43f267e1d1399c68e3ca60f36\" tg-width=\"600\" tg-height=\"371\"><span>E-commerce revenue in the U.S. Data source: Statista</span></p>\n<p>When we take things into clearer perspective by comparing China’s growth rate and size of its market to that of the U.S. e-commerce market, we could see the huge differences in their sizes and growth rates as the U.S. e-commerce market is only expected to grow at a CAGR of 4.67% from 2021 to 2025, which is significantly slower than China’s 12.4%. In addition, the U.S. market is also expected to reach about $563B in total revenue, which is 18% of what the China market is expected to be worth by then.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0d5a8d0d8a6a2dcdf667a6f33c6c9771\" tg-width=\"1280\" tg-height=\"702\"><span>Peers EBIT Margin and Projected EBIT Margin. Data source: S&amp;P Capital IQ</span></p>\n<p>Even though Alibaba has been facing increased competitive pressures from its fast growing key competitors: JD.com(NASDAQ:JD)and Pinduoduo(NASDAQ:PDD), BABA has already been operating a much more profitable business (both EBIT and FCF), and is expected to continue delivering strong profitability moving forward, which should give the company tremendous flexibility to compete head on with JD and PDD in its quest to extend its leadership. Investors may observe that BABA’s EBIT margin was affected by the one-off administrative penalty of $2,782M that was reflected in its SG&amp;A, and therefore skewed its EBIT margin to the downside.</p>\n<p>One important move was the company’s decision to further its investment in the Community Marketplace, which is PDD’s main e-commerce strategy that saw PDD gain a total of&nbsp;823M AAC&nbsp;in its latest quarter as compared to BABA’s 891M AAC. PDD’s AAC growth is truly phenomenal considering it had only&nbsp;100M AAC in Q2’C17&nbsp;as compared to BABA’s 466M AAC in the same period.</p>\n<p>Therefore, the momentum of growth has surely swung over to the Community Marketplace segment and BABA would need to pull out its big guns (which it has) to compete for dominance with PDD and JD.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3b83b69b08b1f4b11a26393c8e6eead5\" tg-width=\"600\" tg-height=\"371\"><span>Market size of community group buying in China. Data source: iiMedia Research</span></p>\n<p>Even though the expected total market size of 102B yuan by 2022 represented only about 21.5% of BABA’s FY 21 China commerce revenue, the expected rapid CAGR of 44.22% over 3 years from 2019 to 2022 cannot be missed by BABA. Although the market is still relatively small, BABA cannot allow the current leader in this market: PDD to so easily dominate and gobble up the early high growth rates at the ignorance of everyone else. Certainly BABA must compete and fight for its place in this segment and strive for early leadership to prevent PDD from extending its lead.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b97b2b4a8a182dc9846d8fb7e4039877\" tg-width=\"1280\" tg-height=\"770\"><span>PDD profitability metrics &amp; revenue growth forecast. Data source: S&amp;P Capital IQ</span></p>\n<p>We could observe from the above chart that PDD is expected to continue growing its revenue rapidly over the next few years, even though they are expected to normalize subsequently. More importantly, PDD is also expected to increasingly improve its EBIT and FCF profitability moving forward. This shows that the Community Marketplace segment is an highly important growth driver that BABA must use its strength to exploit in order to deny PDD’s claim to undisputed leadership so early on in the game.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3aadc32155b4108426a1a982e3b5b1c2\" tg-width=\"640\" tg-height=\"360\"><span>China public cloud spending. Source:China Internet Watch; Canalys</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c1538b9f7bdc8d6d35a72d9acf8ecbc\" tg-width=\"600\" tg-height=\"371\"><span>Size of China public cloud market. Data source: CAICT; Sina.com.cn</span></p>\n<p>BABA has a 40% share in China’s public cloud market, way ahead of its key competitors. However, it’s important to note that despite this leadership, BABA is still in heavy investment mode to continue growing its market share as China’s public cloud market is expected to grow from 26.48B yuan in 2017 to 230.74B yuan by 2023, which would represent a CAGR of 43.4%, an incredibly stellar growth rate. This is especially clear when we compare China’s growth rate to the worldwide growth rate (see below) as public cloud spending worldwide is expected to grow from $145B in 2017 to $397B by 2022, that would represent a CAGR of 22.3%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/06198c569504bc303c34563041dfb294\" tg-width=\"600\" tg-height=\"371\"><span>Worldwide public cloud spending. Data source: Gartner</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8482037f60575f964053ab732496bee3\" tg-width=\"1176\" tg-height=\"700\"><span>Worldwide public cloud market share. Source:CnTechPost; Gartner</span></p>\n<p>Therefore, I don’t find it surprising that Ali Cloud has continued to extend its lead over Alphabet’s(NASDAQ:GOOGL)(NASDAQ:GOOG)GCP with a market share of 9.5% in 2020. While AMZN remains the clear leader in the market, its market share has been coming down considerably as public cloud spending continues to expand, indicating that there is a huge potential for growth for multiple players to exist. With BABA’s leadership in the rapidly expanding Chinese market, I’m increasingly bullish on the future profit and FCF contribution from this segment to BABA’s performance over time. Although BABA’s cloud segment has not been EBIT profitable yet (FY 21 EBIT margin: -15%, FY 20 EBIT margin: -17.5%), it’s also useful to note that GCP has also not been profitable for Alphabet as well (FY 20 EBIT margin: -42.9%, FY 19 EBIT margin: -52%). Therefore, we need to give BABA some time to scale up its cloud services in APAC and in China where it is expected to have stronger leadership to allow it to grow faster and investors should expect this to be a highly profitable segment over time.</p>\n<p><b>BABA's Valuations Look Highly Compelling</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/62a087c4b3ef7efc2c5dde813e3b959d\" tg-width=\"1000\" tg-height=\"600\"><span>NTM TEV / EBIT 3Y range.</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b2605c0e5ad364a7a43929fef204595c\" tg-width=\"1280\" tg-height=\"687\"><span>EV / Fwd EBIT and EV / Fwd Rev trend. Data source: S&amp;P Capital IQ</span></p>\n<p>When we consider BABA's TEV / EBIT historical range, where the 3Y mean read 33.54x, BABA’s EV / Fwd EBIT trend certainly imply a hugely undervalued stock as BABA is still expected to grow its revenue and operating profits rapidly. However, as we wanted to obtain greater clarity over how its counterparts are also valued, we thought it would be useful if we value BABA’s EBIT over a set of benchmark companies that is presented below.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d27873e676dfb23c98d4a69aa5861e02\" tg-width=\"1280\" tg-height=\"1117\"><span>Peers EV / EBIT Valuations. Data source: S&amp;P Capital IQ</span></p>\n<p>By using a blend of historical and forward EBIT, we could see that BABA’s EV / EBIT really looks undervalued when compared to the median value of the set of observed values from the benchmark companies. We derived a fair value range for BABA of $294.98 at the midpoint of the range, that represented a potential upside of 40.5% based on the current stock price of $210.</p>\n<p><b>Risks to Assumptions</b></p>\n<p>Now, it’s obviously baffling to watch how Mr. Market has decided to discount BABA to such an extent as if the company has lost all its key sources of growth, when in fact there is still so much potential upside coming from its commerce segment, the new marketplace initiatives and its growing Ali Cloud segment, among others. The main realistic reason that we identified for the stock's underperformance would simply be regulatory risk. We think investors should acknowledge that this risk is very real and at times huge Chinese companies have found themselves to be subjected to extra scrutiny (which is nothing new in fact) by the Chinese government. What’s critical here is that the Chinese government seemingly has significant clout over the behavior and actions of their tech behemoths that at times may be largely unpredictable. The market certainly hates unpredictability and therefore they may have significantly discounted BABA as a result of that. If investors are not able to handle uncertainty with regard to potentially unpredictable regulatory actions and their aftermath, then BABA may not be appropriate for you. However, if you believe that this is just a blip in BABA’s long journey, then you would surely find BABA's valuations extremely attractive right now, coupled with a long term mindset.</p>\n<p><b>Wrapping It All Up</b></p>\n<p>Alibaba has continued to deliver solid results that demonstrated the strong capability of the company to execute well. As the company continues to operate within a market with so many growth drivers that are expected to drive the company’s future growth, investors should find the current valuations highly attractive.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba Stock: The Bottoming Process Looks To Be Forming Already</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba Stock: The Bottoming Process Looks To Be Forming Already\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4435297-alibaba-stock-bottoming-process-forming-buy-now><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nAlibaba is probably the most undervalued growth stock right now.\nThe company’s multiple growth drivers within a rapidly expanding market made its valuations look even more baffling.\nThe short...</p>\n\n<a href=\"https://seekingalpha.com/article/4435297-alibaba-stock-bottoming-process-forming-buy-now\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","09988":"阿里巴巴-W"},"source_url":"https://seekingalpha.com/article/4435297-alibaba-stock-bottoming-process-forming-buy-now","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175693382","content_text":"Summary\n\nAlibaba is probably the most undervalued growth stock right now.\nThe company’s multiple growth drivers within a rapidly expanding market made its valuations look even more baffling.\nThe short term technical picture may be turning bullish with a potential double bottom price action signal.\nWe discuss the company’s multiple growth drivers and let investors judge for themselves.\n\nYongyuan Dai/iStock Unreleased via Getty Images\nThe Technical Thesis\nSource: TradingView\nAlibaba’s stock price has endured a terrible 8 months ever since its Ant Financial IPO was pulled in early Nov 20, with the stock languishing in the doldrums 34% off its high. When considering the health of its long term uptrend, it’s clear that BABA has a relatively strong uptrend bias and has generally been well supported along its key 50W MA. The only other time in the last 4 years that it lost its key 50W MA support level was during the 2018 bear market where BABA dropped about 40%, but was still well supported above the important 200W MA, which we usually consider as the “last line of defense”. Right now BABA is somewhat facing a similar situation again: down 34%, lost the 50W MA, but looks to be well supported above the 200W MA. In addition to that, one interesting observation in price action analysis may lead price action traders/investors to be especially bullish: a potential double bottom formation. BABA's price is seemingly going through a double bottom like it did during the 2018 bear market before it rallied strongly thereafter. As a result, BABA’s current level may offer a possible technical buy entry point now.\nBABA's Fundamental Thesis: Rapidly Expanding Growth Drivers\nAnnual GMV. Data source: Company filings\nAnnual e-commerce revenue. Data source: Company filings\nBABA’s GMV grew from 1.68T yuan to 7.49T yuan in just a matter of 7 years, which represented a CAGR of 23.8%, a truly amazing growth rate. We also saw its GMV growth being converted into revenue growth as its China commerce revenue grew from 7.67B yuan to 473.68B yuan, at a CAGR of 51% over the last 10 years. While its international footprint remains considerably smaller, it still grew at a CAGR of 30.42% over the last 10 years, which was by no means slow.\nEven though China’s e-commerce market is expected to grow considerably slower at a CAGR of 12.4% over the next three years, from 13.8T yuan, equivalent to $2.16T in 2021 to 19.6T yuan,equivalent to $3.06T by 2024, the massive size of the market still offers tremendous upside potential for BABA and its closest competitors to grow into.\nE-commerce revenue in the U.S. Data source: Statista\nWhen we take things into clearer perspective by comparing China’s growth rate and size of its market to that of the U.S. e-commerce market, we could see the huge differences in their sizes and growth rates as the U.S. e-commerce market is only expected to grow at a CAGR of 4.67% from 2021 to 2025, which is significantly slower than China’s 12.4%. In addition, the U.S. market is also expected to reach about $563B in total revenue, which is 18% of what the China market is expected to be worth by then.\nPeers EBIT Margin and Projected EBIT Margin. Data source: S&P Capital IQ\nEven though Alibaba has been facing increased competitive pressures from its fast growing key competitors: JD.com(NASDAQ:JD)and Pinduoduo(NASDAQ:PDD), BABA has already been operating a much more profitable business (both EBIT and FCF), and is expected to continue delivering strong profitability moving forward, which should give the company tremendous flexibility to compete head on with JD and PDD in its quest to extend its leadership. Investors may observe that BABA’s EBIT margin was affected by the one-off administrative penalty of $2,782M that was reflected in its SG&A, and therefore skewed its EBIT margin to the downside.\nOne important move was the company’s decision to further its investment in the Community Marketplace, which is PDD’s main e-commerce strategy that saw PDD gain a total of 823M AAC in its latest quarter as compared to BABA’s 891M AAC. PDD’s AAC growth is truly phenomenal considering it had only 100M AAC in Q2’C17 as compared to BABA’s 466M AAC in the same period.\nTherefore, the momentum of growth has surely swung over to the Community Marketplace segment and BABA would need to pull out its big guns (which it has) to compete for dominance with PDD and JD.\nMarket size of community group buying in China. Data source: iiMedia Research\nEven though the expected total market size of 102B yuan by 2022 represented only about 21.5% of BABA’s FY 21 China commerce revenue, the expected rapid CAGR of 44.22% over 3 years from 2019 to 2022 cannot be missed by BABA. Although the market is still relatively small, BABA cannot allow the current leader in this market: PDD to so easily dominate and gobble up the early high growth rates at the ignorance of everyone else. Certainly BABA must compete and fight for its place in this segment and strive for early leadership to prevent PDD from extending its lead.\nPDD profitability metrics & revenue growth forecast. Data source: S&P Capital IQ\nWe could observe from the above chart that PDD is expected to continue growing its revenue rapidly over the next few years, even though they are expected to normalize subsequently. More importantly, PDD is also expected to increasingly improve its EBIT and FCF profitability moving forward. This shows that the Community Marketplace segment is an highly important growth driver that BABA must use its strength to exploit in order to deny PDD’s claim to undisputed leadership so early on in the game.\nChina public cloud spending. Source:China Internet Watch; Canalys\nSize of China public cloud market. Data source: CAICT; Sina.com.cn\nBABA has a 40% share in China’s public cloud market, way ahead of its key competitors. However, it’s important to note that despite this leadership, BABA is still in heavy investment mode to continue growing its market share as China’s public cloud market is expected to grow from 26.48B yuan in 2017 to 230.74B yuan by 2023, which would represent a CAGR of 43.4%, an incredibly stellar growth rate. This is especially clear when we compare China’s growth rate to the worldwide growth rate (see below) as public cloud spending worldwide is expected to grow from $145B in 2017 to $397B by 2022, that would represent a CAGR of 22.3%.\nWorldwide public cloud spending. Data source: Gartner\nWorldwide public cloud market share. Source:CnTechPost; Gartner\nTherefore, I don’t find it surprising that Ali Cloud has continued to extend its lead over Alphabet’s(NASDAQ:GOOGL)(NASDAQ:GOOG)GCP with a market share of 9.5% in 2020. While AMZN remains the clear leader in the market, its market share has been coming down considerably as public cloud spending continues to expand, indicating that there is a huge potential for growth for multiple players to exist. With BABA’s leadership in the rapidly expanding Chinese market, I’m increasingly bullish on the future profit and FCF contribution from this segment to BABA’s performance over time. Although BABA’s cloud segment has not been EBIT profitable yet (FY 21 EBIT margin: -15%, FY 20 EBIT margin: -17.5%), it’s also useful to note that GCP has also not been profitable for Alphabet as well (FY 20 EBIT margin: -42.9%, FY 19 EBIT margin: -52%). Therefore, we need to give BABA some time to scale up its cloud services in APAC and in China where it is expected to have stronger leadership to allow it to grow faster and investors should expect this to be a highly profitable segment over time.\nBABA's Valuations Look Highly Compelling\nNTM TEV / EBIT 3Y range.\nEV / Fwd EBIT and EV / Fwd Rev trend. Data source: S&P Capital IQ\nWhen we consider BABA's TEV / EBIT historical range, where the 3Y mean read 33.54x, BABA’s EV / Fwd EBIT trend certainly imply a hugely undervalued stock as BABA is still expected to grow its revenue and operating profits rapidly. However, as we wanted to obtain greater clarity over how its counterparts are also valued, we thought it would be useful if we value BABA’s EBIT over a set of benchmark companies that is presented below.\nPeers EV / EBIT Valuations. Data source: S&P Capital IQ\nBy using a blend of historical and forward EBIT, we could see that BABA’s EV / EBIT really looks undervalued when compared to the median value of the set of observed values from the benchmark companies. We derived a fair value range for BABA of $294.98 at the midpoint of the range, that represented a potential upside of 40.5% based on the current stock price of $210.\nRisks to Assumptions\nNow, it’s obviously baffling to watch how Mr. Market has decided to discount BABA to such an extent as if the company has lost all its key sources of growth, when in fact there is still so much potential upside coming from its commerce segment, the new marketplace initiatives and its growing Ali Cloud segment, among others. The main realistic reason that we identified for the stock's underperformance would simply be regulatory risk. We think investors should acknowledge that this risk is very real and at times huge Chinese companies have found themselves to be subjected to extra scrutiny (which is nothing new in fact) by the Chinese government. What’s critical here is that the Chinese government seemingly has significant clout over the behavior and actions of their tech behemoths that at times may be largely unpredictable. The market certainly hates unpredictability and therefore they may have significantly discounted BABA as a result of that. If investors are not able to handle uncertainty with regard to potentially unpredictable regulatory actions and their aftermath, then BABA may not be appropriate for you. However, if you believe that this is just a blip in BABA’s long journey, then you would surely find BABA's valuations extremely attractive right now, coupled with a long term mindset.\nWrapping It All Up\nAlibaba has continued to deliver solid results that demonstrated the strong capability of the company to execute well. As the company continues to operate within a market with so many growth drivers that are expected to drive the company’s future growth, investors should find the current valuations highly attractive.","news_type":1},"isVote":1,"tweetType":1,"viewCount":582,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188052503,"gmtCreate":1623417708202,"gmtModify":1704203059698,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Likes","listText":"Likes","text":"Likes","images":[{"img":"https://static.tigerbbs.com/502a995361f770610b850e5da688999c","width":"1080","height":"2070"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/188052503","isVote":1,"tweetType":1,"viewCount":411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":183257494,"gmtCreate":1623333828518,"gmtModify":1704201156974,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Lnc","listText":"Lnc","text":"Lnc","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/183257494","repostId":"1106213554","repostType":4,"isVote":1,"tweetType":1,"viewCount":623,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":116347083,"gmtCreate":1622777184442,"gmtModify":1704190998299,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Woo","listText":"Woo","text":"Woo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/116347083","repostId":"2140026421","repostType":4,"repost":{"id":"2140026421","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1622775272,"share":"https://ttm.financial/m/news/2140026421?lang=&edition=fundamental","pubTime":"2021-06-04 10:54","market":"hk","language":"en","title":"Here's AMC's blunt new warning to prospective buyers of its new stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2140026421","media":"Dow Jones","summary":"AMC Entertainment Holdings on Thursday announced a new stock sale to take advantage of the extraordi","content":"<p>AMC Entertainment Holdings on Thursday announced a new stock sale to take advantage of the extraordinary retail interest that has driven the movie-theater chain's equity up by 2,850% this year.</p><p>AMC's <a href=\"https://laohu8.com/S/AMC\">$(AMC)$</a> lawyers are apparently as surprised as anyone -- so much so that the company added a fresh risk factor to its 11 million--share sale, which basically boils down to this warning: Prepare to lose everything if you buy the stock.</p><p>The following is the full, extraordinary warning (bolded and italicized text reproduced as in AMC prospectus):</p><p>The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses.</p><p>The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses. For example, during 2021 to date, the market price of our Class A common stock has fluctuated from an intra-day low of $1.91 per share on January 5, 2021 to an intra-day high on the NYSE of $72.62 on June 2, 2021 and the last reported sale price of our Class A common stock on the NYSE on June 2, 2021, was $62.55 per share. During 2021 to date, daily trading volume ranged from approximately 23,598,228 to 1,253,253,550 shares. Within the last seven business days, the market price of our Class A common stock has fluctuated from an intra-day low of $12.18 on May 24, 2021 to an intra-day high of $72.62 on June 2, 2021, and we have made no disclosure regarding a change to our underlying business during that period, other than with respect to an additional financing.</p><p>We believe that the recent volatility and our current market prices reflect market and trading dynamics unrelated to our underlying business, or macro or industry fundamentals, and we do not know how long these dynamics will last. Under the circumstances, we caution you against investing in our Class A common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.</p><p>Extreme fluctuations in the market price of our Class A common stock have been accompanied by reports of strong and atypical retail investor interest, including on social media and online forums. The market volatility and trading patterns we have experienced create several risks for investors, including the following:</p><ul><li>the market price of our Class A common stock has experienced and may continue to experience rapid and substantial increases or decreases unrelated to our operating performance or prospects, or macro or industry fundamentals, and substantial increases may be significantly inconsistent with the risks and uncertainties that we continue to face;</li><li>factors in the public trading market for our Class A common stock include the sentiment of retail investors (including as may be expressed on financial trading and other social media sites and online forums), the direct access by retail investors to broadly available trading platforms, the amount and status of short interest in our securities, access to margin debt, trading in options and other derivatives on our Class A common stock and any related hedging and other trading factors;</li><li>our market capitalization, as implied by various trading prices, currently reflects valuations that diverge significantly from those seen prior to recent volatility and that are significantly higher than our market capitalization immediately prior to the COVID-19 pandemic, and to the extent these valuations reflect trading dynamics unrelated to our financial performance or prospects, purchasers of our Class A common stock could incur substantial losses if there are declines in market prices driven by a return to earlier valuations;</li><li>to the extent volatility in our Class A common stock is caused, as has widely been reported, by a “short squeeze” in which coordinated trading activity causes a spike in the market price of our Class A common stock as traders with a short position make market purchases to avoid or to mitigate potential losses, investors purchase at inflated prices unrelated to our financial performance or prospects, and may thereafter suffer substantial losses as prices decline once the level of short-covering purchases has abated; and</li><li>if the market price of our Class A common stock declines, you may be unable to resell your shares at or above the price at which you acquired them. We cannot assure you that the equity issuance of our Class A common stock will not fluctuate or decline significantly in the future, in which case you could incur substantial losses.</li></ul><p>We may continue to incur rapid and substantial increases or decreases in our stock price in the foreseeable future that may not coincide in timing with the disclosure of news or developments by or affecting us. Accordingly, the market price of our shares of Class A common stock may fluctuate dramatically, and may decline rapidly, regardless of any developments in our business.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's AMC's blunt new warning to prospective buyers of its new stock offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's AMC's blunt new warning to prospective buyers of its new stock offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-04 10:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMC Entertainment Holdings on Thursday announced a new stock sale to take advantage of the extraordinary retail interest that has driven the movie-theater chain's equity up by 2,850% this year.</p><p>AMC's <a href=\"https://laohu8.com/S/AMC\">$(AMC)$</a> lawyers are apparently as surprised as anyone -- so much so that the company added a fresh risk factor to its 11 million--share sale, which basically boils down to this warning: Prepare to lose everything if you buy the stock.</p><p>The following is the full, extraordinary warning (bolded and italicized text reproduced as in AMC prospectus):</p><p>The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses.</p><p>The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses. For example, during 2021 to date, the market price of our Class A common stock has fluctuated from an intra-day low of $1.91 per share on January 5, 2021 to an intra-day high on the NYSE of $72.62 on June 2, 2021 and the last reported sale price of our Class A common stock on the NYSE on June 2, 2021, was $62.55 per share. During 2021 to date, daily trading volume ranged from approximately 23,598,228 to 1,253,253,550 shares. Within the last seven business days, the market price of our Class A common stock has fluctuated from an intra-day low of $12.18 on May 24, 2021 to an intra-day high of $72.62 on June 2, 2021, and we have made no disclosure regarding a change to our underlying business during that period, other than with respect to an additional financing.</p><p>We believe that the recent volatility and our current market prices reflect market and trading dynamics unrelated to our underlying business, or macro or industry fundamentals, and we do not know how long these dynamics will last. Under the circumstances, we caution you against investing in our Class A common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.</p><p>Extreme fluctuations in the market price of our Class A common stock have been accompanied by reports of strong and atypical retail investor interest, including on social media and online forums. The market volatility and trading patterns we have experienced create several risks for investors, including the following:</p><ul><li>the market price of our Class A common stock has experienced and may continue to experience rapid and substantial increases or decreases unrelated to our operating performance or prospects, or macro or industry fundamentals, and substantial increases may be significantly inconsistent with the risks and uncertainties that we continue to face;</li><li>factors in the public trading market for our Class A common stock include the sentiment of retail investors (including as may be expressed on financial trading and other social media sites and online forums), the direct access by retail investors to broadly available trading platforms, the amount and status of short interest in our securities, access to margin debt, trading in options and other derivatives on our Class A common stock and any related hedging and other trading factors;</li><li>our market capitalization, as implied by various trading prices, currently reflects valuations that diverge significantly from those seen prior to recent volatility and that are significantly higher than our market capitalization immediately prior to the COVID-19 pandemic, and to the extent these valuations reflect trading dynamics unrelated to our financial performance or prospects, purchasers of our Class A common stock could incur substantial losses if there are declines in market prices driven by a return to earlier valuations;</li><li>to the extent volatility in our Class A common stock is caused, as has widely been reported, by a “short squeeze” in which coordinated trading activity causes a spike in the market price of our Class A common stock as traders with a short position make market purchases to avoid or to mitigate potential losses, investors purchase at inflated prices unrelated to our financial performance or prospects, and may thereafter suffer substantial losses as prices decline once the level of short-covering purchases has abated; and</li><li>if the market price of our Class A common stock declines, you may be unable to resell your shares at or above the price at which you acquired them. We cannot assure you that the equity issuance of our Class A common stock will not fluctuate or decline significantly in the future, in which case you could incur substantial losses.</li></ul><p>We may continue to incur rapid and substantial increases or decreases in our stock price in the foreseeable future that may not coincide in timing with the disclosure of news or developments by or affecting us. Accordingly, the market price of our shares of Class A common stock may fluctuate dramatically, and may decline rapidly, regardless of any developments in our business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140026421","content_text":"AMC Entertainment Holdings on Thursday announced a new stock sale to take advantage of the extraordinary retail interest that has driven the movie-theater chain's equity up by 2,850% this year.AMC's $(AMC)$ lawyers are apparently as surprised as anyone -- so much so that the company added a fresh risk factor to its 11 million--share sale, which basically boils down to this warning: Prepare to lose everything if you buy the stock.The following is the full, extraordinary warning (bolded and italicized text reproduced as in AMC prospectus):The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses.The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses. For example, during 2021 to date, the market price of our Class A common stock has fluctuated from an intra-day low of $1.91 per share on January 5, 2021 to an intra-day high on the NYSE of $72.62 on June 2, 2021 and the last reported sale price of our Class A common stock on the NYSE on June 2, 2021, was $62.55 per share. During 2021 to date, daily trading volume ranged from approximately 23,598,228 to 1,253,253,550 shares. Within the last seven business days, the market price of our Class A common stock has fluctuated from an intra-day low of $12.18 on May 24, 2021 to an intra-day high of $72.62 on June 2, 2021, and we have made no disclosure regarding a change to our underlying business during that period, other than with respect to an additional financing.We believe that the recent volatility and our current market prices reflect market and trading dynamics unrelated to our underlying business, or macro or industry fundamentals, and we do not know how long these dynamics will last. Under the circumstances, we caution you against investing in our Class A common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.Extreme fluctuations in the market price of our Class A common stock have been accompanied by reports of strong and atypical retail investor interest, including on social media and online forums. The market volatility and trading patterns we have experienced create several risks for investors, including the following:the market price of our Class A common stock has experienced and may continue to experience rapid and substantial increases or decreases unrelated to our operating performance or prospects, or macro or industry fundamentals, and substantial increases may be significantly inconsistent with the risks and uncertainties that we continue to face;factors in the public trading market for our Class A common stock include the sentiment of retail investors (including as may be expressed on financial trading and other social media sites and online forums), the direct access by retail investors to broadly available trading platforms, the amount and status of short interest in our securities, access to margin debt, trading in options and other derivatives on our Class A common stock and any related hedging and other trading factors;our market capitalization, as implied by various trading prices, currently reflects valuations that diverge significantly from those seen prior to recent volatility and that are significantly higher than our market capitalization immediately prior to the COVID-19 pandemic, and to the extent these valuations reflect trading dynamics unrelated to our financial performance or prospects, purchasers of our Class A common stock could incur substantial losses if there are declines in market prices driven by a return to earlier valuations;to the extent volatility in our Class A common stock is caused, as has widely been reported, by a “short squeeze” in which coordinated trading activity causes a spike in the market price of our Class A common stock as traders with a short position make market purchases to avoid or to mitigate potential losses, investors purchase at inflated prices unrelated to our financial performance or prospects, and may thereafter suffer substantial losses as prices decline once the level of short-covering purchases has abated; andif the market price of our Class A common stock declines, you may be unable to resell your shares at or above the price at which you acquired them. We cannot assure you that the equity issuance of our Class A common stock will not fluctuate or decline significantly in the future, in which case you could incur substantial losses.We may continue to incur rapid and substantial increases or decreases in our stock price in the foreseeable future that may not coincide in timing with the disclosure of news or developments by or affecting us. Accordingly, the market price of our shares of Class A common stock may fluctuate dramatically, and may decline rapidly, regardless of any developments in our business.","news_type":1},"isVote":1,"tweetType":1,"viewCount":461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119188724,"gmtCreate":1622527253568,"gmtModify":1704185668259,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Tesla","listText":"Tesla","text":"Tesla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/119188724","repostId":"2140545174","repostType":4,"isVote":1,"tweetType":1,"viewCount":491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119188360,"gmtCreate":1622527221550,"gmtModify":1704185667602,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Tesla","listText":"Tesla","text":"Tesla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/119188360","repostId":"1133436315","repostType":4,"isVote":1,"tweetType":1,"viewCount":535,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119183707,"gmtCreate":1622527172009,"gmtModify":1704185664968,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119183707","repostId":"1133436315","repostType":4,"isVote":1,"tweetType":1,"viewCount":617,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119183019,"gmtCreate":1622527112131,"gmtModify":1704185663812,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Like &amp; comm","listText":"Like &amp; comm","text":"Like & comm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119183019","repostId":"2139304437","repostType":4,"repost":{"id":"2139304437","pubTimestamp":1622513653,"share":"https://ttm.financial/m/news/2139304437?lang=&edition=fundamental","pubTime":"2021-06-01 10:14","market":"us","language":"en","title":"Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2139304437","media":"Motley Fool","summary":"Even a modest investment in these unstoppable stocks could reap huge rewards over the next decade.","content":"<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad <a href=\"https://laohu8.com/S/AONE\">one</a>.</p>\n<p>Here are two low-priced stocks that long-term investors should consider scooping up right now.</p>\n<p><img src=\"https://static.tigerbbs.com/ab4cdcd429fc79807e5230a73da31639\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h2>1. Jushi Holdings</h2>\n<p>Trading for less than $6 per share at the time of this writing, <b>Jushi Holdings</b> (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.</p>\n<p>2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.</p>\n<p>Jushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.</p>\n<p>The company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of <a href=\"https://laohu8.com/S/AONE.U\">one</a> of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.</p>\n<p>As Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.</p>\n<h2>2. <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></h2>\n<p><b>Pfizer</b> (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, <b>BioNTech </b>-- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.</p>\n<p>Pfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.</p>\n<p>During the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.</p>\n<p>In addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.</p>\n<p>Pfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHave $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 10:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISBC":"投资者银行"},"source_url":"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2139304437","content_text":"There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad one.\nHere are two low-priced stocks that long-term investors should consider scooping up right now.\n\nImage source: Getty Images.\n1. Jushi Holdings\nTrading for less than $6 per share at the time of this writing, Jushi Holdings (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.\n2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.\nJushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.\nThe company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of one of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.\nAs Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.\n2. Pfizer\nPfizer (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, BioNTech -- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.\nPfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.\nDuring the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.\nIn addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.\nPfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":505,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119189835,"gmtCreate":1622527036727,"gmtModify":1704185663159,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119189835","repostId":"2139304437","repostType":4,"repost":{"id":"2139304437","pubTimestamp":1622513653,"share":"https://ttm.financial/m/news/2139304437?lang=&edition=fundamental","pubTime":"2021-06-01 10:14","market":"us","language":"en","title":"Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2139304437","media":"Motley Fool","summary":"Even a modest investment in these unstoppable stocks could reap huge rewards over the next decade.","content":"<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad <a href=\"https://laohu8.com/S/AONE\">one</a>.</p>\n<p>Here are two low-priced stocks that long-term investors should consider scooping up right now.</p>\n<p><img src=\"https://static.tigerbbs.com/ab4cdcd429fc79807e5230a73da31639\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h2>1. Jushi Holdings</h2>\n<p>Trading for less than $6 per share at the time of this writing, <b>Jushi Holdings</b> (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.</p>\n<p>2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.</p>\n<p>Jushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.</p>\n<p>The company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of <a href=\"https://laohu8.com/S/AONE.U\">one</a> of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.</p>\n<p>As Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.</p>\n<h2>2. <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></h2>\n<p><b>Pfizer</b> (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, <b>BioNTech </b>-- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.</p>\n<p>Pfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.</p>\n<p>During the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.</p>\n<p>In addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.</p>\n<p>Pfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHave $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 10:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISBC":"投资者银行"},"source_url":"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2139304437","content_text":"There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad one.\nHere are two low-priced stocks that long-term investors should consider scooping up right now.\n\nImage source: Getty Images.\n1. Jushi Holdings\nTrading for less than $6 per share at the time of this writing, Jushi Holdings (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.\n2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.\nJushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.\nThe company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of one of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.\nAs Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.\n2. Pfizer\nPfizer (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, BioNTech -- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.\nPfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.\nDuring the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.\nIn addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.\nPfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119189074,"gmtCreate":1622527004698,"gmtModify":1704185662345,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Like &amp; comm","listText":"Like &amp; comm","text":"Like & comm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119189074","repostId":"2139304437","repostType":4,"repost":{"id":"2139304437","pubTimestamp":1622513653,"share":"https://ttm.financial/m/news/2139304437?lang=&edition=fundamental","pubTime":"2021-06-01 10:14","market":"us","language":"en","title":"Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2139304437","media":"Motley Fool","summary":"Even a modest investment in these unstoppable stocks could reap huge rewards over the next decade.","content":"<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad <a href=\"https://laohu8.com/S/AONE\">one</a>.</p>\n<p>Here are two low-priced stocks that long-term investors should consider scooping up right now.</p>\n<p><img src=\"https://static.tigerbbs.com/ab4cdcd429fc79807e5230a73da31639\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h2>1. Jushi Holdings</h2>\n<p>Trading for less than $6 per share at the time of this writing, <b>Jushi Holdings</b> (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.</p>\n<p>2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.</p>\n<p>Jushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.</p>\n<p>The company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of <a href=\"https://laohu8.com/S/AONE.U\">one</a> of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.</p>\n<p>As Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.</p>\n<h2>2. <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></h2>\n<p><b>Pfizer</b> (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, <b>BioNTech </b>-- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.</p>\n<p>Pfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.</p>\n<p>During the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.</p>\n<p>In addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.</p>\n<p>Pfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHave $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 10:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISBC":"投资者银行"},"source_url":"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2139304437","content_text":"There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad one.\nHere are two low-priced stocks that long-term investors should consider scooping up right now.\n\nImage source: Getty Images.\n1. Jushi Holdings\nTrading for less than $6 per share at the time of this writing, Jushi Holdings (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.\n2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.\nJushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.\nThe company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of one of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.\nAs Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.\n2. Pfizer\nPfizer (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, BioNTech -- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.\nPfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.\nDuring the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.\nIn addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.\nPfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":476,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":138504516,"gmtCreate":1621947871935,"gmtModify":1704364932386,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Like &amp; comm","listText":"Like &amp; comm","text":"Like & comm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/138504516","repostId":"2138167226","repostType":4,"isVote":1,"tweetType":1,"viewCount":503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":138504079,"gmtCreate":1621947822791,"gmtModify":1704364931555,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584575502696721","idStr":"3584575502696721"},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/138504079","repostId":"2138116154","repostType":4,"isVote":1,"tweetType":1,"viewCount":257,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":168556210,"gmtCreate":1623979283330,"gmtModify":1703825296747,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Feat","listText":"Feat","text":"Feat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":14,"repostSize":0,"link":"https://ttm.financial/post/168556210","repostId":"1175693382","repostType":4,"repost":{"id":"1175693382","pubTimestamp":1623978463,"share":"https://ttm.financial/m/news/1175693382?lang=&edition=fundamental","pubTime":"2021-06-18 09:07","market":"hk","language":"en","title":"Alibaba Stock: The Bottoming Process Looks To Be Forming Already","url":"https://stock-news.laohu8.com/highlight/detail?id=1175693382","media":"seekingalpha","summary":"Alibaba is probably the most undervalued growth stock right now.The company’s multiple growth drivers within a rapidly expanding market made its valuations look even more baffling.The short term technical picture may be turning bullish with a potential double bottom price action signal.When we take things into clearer perspective by comparing China’s growth rate and size of its market to that of the U.S. e-commerce market, we could see the huge differences in their sizes and growth rates as the ","content":"<p><b>Summary</b></p>\n<ul>\n <li>Alibaba is probably the most undervalued growth stock right now.</li>\n <li>The company’s multiple growth drivers within a rapidly expanding market made its valuations look even more baffling.</li>\n <li>The short term technical picture may be turning bullish with a potential double bottom price action signal.</li>\n <li>We discuss the company’s multiple growth drivers and let investors judge for themselves.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/05e63c77d4f3f3dc3d618e43044638bb\" tg-width=\"768\" tg-height=\"512\"><span>Yongyuan Dai/iStock Unreleased via Getty Images</span></p>\n<p><b>The Technical Thesis</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7febf6ed056b0e3bc038321cdaad9b1c\" tg-width=\"1280\" tg-height=\"782\"><span>Source: TradingView</span></p>\n<p>Alibaba’s&nbsp;stock price has endured a terrible 8 months ever since its Ant Financial IPO was pulled in early Nov 20, with the stock languishing in the doldrums 34% off its high. When considering the health of its long term uptrend, it’s clear that BABA has a relatively strong uptrend bias and has generally been well supported along its key 50W MA. The only other time in the last 4 years that it lost its key 50W MA support level was during the 2018 bear market where BABA dropped about 40%, but was still well supported above the important 200W MA, which we usually consider as the “last line of defense”. Right now BABA is somewhat facing a similar situation again: down 34%, lost the 50W MA, but looks to be well supported above the 200W MA. In addition to that, one interesting observation in price action analysis may lead price action traders/investors to be especially bullish: a potential double bottom formation. BABA's price is seemingly going through a double bottom like it did during the 2018 bear market before it rallied strongly thereafter. As a result, BABA’s current level may offer a possible technical buy entry point now.</p>\n<p><b>BABA's Fundamental Thesis: Rapidly Expanding Growth Drivers</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eba49f5881708929949c30628eedc5d4\" tg-width=\"934\" tg-height=\"578\"><span>Annual GMV. Data source: Company filings</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a4d6c4ed3e2402f5af52b2dea8bab411\" tg-width=\"836\" tg-height=\"517\"><span>Annual e-commerce revenue. Data source: Company filings</span></p>\n<p>BABA’s GMV grew from 1.68T yuan to 7.49T yuan in just a matter of 7 years, which represented a CAGR of 23.8%, a truly amazing growth rate. We also saw its GMV growth being converted into revenue growth as its China commerce revenue grew from 7.67B yuan to 473.68B yuan, at a CAGR of 51% over the last 10 years. While its international footprint remains considerably smaller, it still grew at a CAGR of 30.42% over the last 10 years, which was by no means slow.</p>\n<p>Even though China’s e-commerce market is expected to grow considerably slower at a CAGR of 12.4% over the next three years, from 13.8T yuan, equivalent to $2.16T in 2021 to 19.6T yuan,equivalent to $3.06T by 2024, the massive size of the market still offers tremendous upside potential for BABA and its closest competitors to grow into.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ffe2dee43f267e1d1399c68e3ca60f36\" tg-width=\"600\" tg-height=\"371\"><span>E-commerce revenue in the U.S. Data source: Statista</span></p>\n<p>When we take things into clearer perspective by comparing China’s growth rate and size of its market to that of the U.S. e-commerce market, we could see the huge differences in their sizes and growth rates as the U.S. e-commerce market is only expected to grow at a CAGR of 4.67% from 2021 to 2025, which is significantly slower than China’s 12.4%. In addition, the U.S. market is also expected to reach about $563B in total revenue, which is 18% of what the China market is expected to be worth by then.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0d5a8d0d8a6a2dcdf667a6f33c6c9771\" tg-width=\"1280\" tg-height=\"702\"><span>Peers EBIT Margin and Projected EBIT Margin. Data source: S&amp;P Capital IQ</span></p>\n<p>Even though Alibaba has been facing increased competitive pressures from its fast growing key competitors: JD.com(NASDAQ:JD)and Pinduoduo(NASDAQ:PDD), BABA has already been operating a much more profitable business (both EBIT and FCF), and is expected to continue delivering strong profitability moving forward, which should give the company tremendous flexibility to compete head on with JD and PDD in its quest to extend its leadership. Investors may observe that BABA’s EBIT margin was affected by the one-off administrative penalty of $2,782M that was reflected in its SG&amp;A, and therefore skewed its EBIT margin to the downside.</p>\n<p>One important move was the company’s decision to further its investment in the Community Marketplace, which is PDD’s main e-commerce strategy that saw PDD gain a total of&nbsp;823M AAC&nbsp;in its latest quarter as compared to BABA’s 891M AAC. PDD’s AAC growth is truly phenomenal considering it had only&nbsp;100M AAC in Q2’C17&nbsp;as compared to BABA’s 466M AAC in the same period.</p>\n<p>Therefore, the momentum of growth has surely swung over to the Community Marketplace segment and BABA would need to pull out its big guns (which it has) to compete for dominance with PDD and JD.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3b83b69b08b1f4b11a26393c8e6eead5\" tg-width=\"600\" tg-height=\"371\"><span>Market size of community group buying in China. Data source: iiMedia Research</span></p>\n<p>Even though the expected total market size of 102B yuan by 2022 represented only about 21.5% of BABA’s FY 21 China commerce revenue, the expected rapid CAGR of 44.22% over 3 years from 2019 to 2022 cannot be missed by BABA. Although the market is still relatively small, BABA cannot allow the current leader in this market: PDD to so easily dominate and gobble up the early high growth rates at the ignorance of everyone else. Certainly BABA must compete and fight for its place in this segment and strive for early leadership to prevent PDD from extending its lead.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b97b2b4a8a182dc9846d8fb7e4039877\" tg-width=\"1280\" tg-height=\"770\"><span>PDD profitability metrics &amp; revenue growth forecast. Data source: S&amp;P Capital IQ</span></p>\n<p>We could observe from the above chart that PDD is expected to continue growing its revenue rapidly over the next few years, even though they are expected to normalize subsequently. More importantly, PDD is also expected to increasingly improve its EBIT and FCF profitability moving forward. This shows that the Community Marketplace segment is an highly important growth driver that BABA must use its strength to exploit in order to deny PDD’s claim to undisputed leadership so early on in the game.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3aadc32155b4108426a1a982e3b5b1c2\" tg-width=\"640\" tg-height=\"360\"><span>China public cloud spending. Source:China Internet Watch; Canalys</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c1538b9f7bdc8d6d35a72d9acf8ecbc\" tg-width=\"600\" tg-height=\"371\"><span>Size of China public cloud market. Data source: CAICT; Sina.com.cn</span></p>\n<p>BABA has a 40% share in China’s public cloud market, way ahead of its key competitors. However, it’s important to note that despite this leadership, BABA is still in heavy investment mode to continue growing its market share as China’s public cloud market is expected to grow from 26.48B yuan in 2017 to 230.74B yuan by 2023, which would represent a CAGR of 43.4%, an incredibly stellar growth rate. This is especially clear when we compare China’s growth rate to the worldwide growth rate (see below) as public cloud spending worldwide is expected to grow from $145B in 2017 to $397B by 2022, that would represent a CAGR of 22.3%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/06198c569504bc303c34563041dfb294\" tg-width=\"600\" tg-height=\"371\"><span>Worldwide public cloud spending. Data source: Gartner</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8482037f60575f964053ab732496bee3\" tg-width=\"1176\" tg-height=\"700\"><span>Worldwide public cloud market share. Source:CnTechPost; Gartner</span></p>\n<p>Therefore, I don’t find it surprising that Ali Cloud has continued to extend its lead over Alphabet’s(NASDAQ:GOOGL)(NASDAQ:GOOG)GCP with a market share of 9.5% in 2020. While AMZN remains the clear leader in the market, its market share has been coming down considerably as public cloud spending continues to expand, indicating that there is a huge potential for growth for multiple players to exist. With BABA’s leadership in the rapidly expanding Chinese market, I’m increasingly bullish on the future profit and FCF contribution from this segment to BABA’s performance over time. Although BABA’s cloud segment has not been EBIT profitable yet (FY 21 EBIT margin: -15%, FY 20 EBIT margin: -17.5%), it’s also useful to note that GCP has also not been profitable for Alphabet as well (FY 20 EBIT margin: -42.9%, FY 19 EBIT margin: -52%). Therefore, we need to give BABA some time to scale up its cloud services in APAC and in China where it is expected to have stronger leadership to allow it to grow faster and investors should expect this to be a highly profitable segment over time.</p>\n<p><b>BABA's Valuations Look Highly Compelling</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/62a087c4b3ef7efc2c5dde813e3b959d\" tg-width=\"1000\" tg-height=\"600\"><span>NTM TEV / EBIT 3Y range.</span></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b2605c0e5ad364a7a43929fef204595c\" tg-width=\"1280\" tg-height=\"687\"><span>EV / Fwd EBIT and EV / Fwd Rev trend. Data source: S&amp;P Capital IQ</span></p>\n<p>When we consider BABA's TEV / EBIT historical range, where the 3Y mean read 33.54x, BABA’s EV / Fwd EBIT trend certainly imply a hugely undervalued stock as BABA is still expected to grow its revenue and operating profits rapidly. However, as we wanted to obtain greater clarity over how its counterparts are also valued, we thought it would be useful if we value BABA’s EBIT over a set of benchmark companies that is presented below.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d27873e676dfb23c98d4a69aa5861e02\" tg-width=\"1280\" tg-height=\"1117\"><span>Peers EV / EBIT Valuations. Data source: S&amp;P Capital IQ</span></p>\n<p>By using a blend of historical and forward EBIT, we could see that BABA’s EV / EBIT really looks undervalued when compared to the median value of the set of observed values from the benchmark companies. We derived a fair value range for BABA of $294.98 at the midpoint of the range, that represented a potential upside of 40.5% based on the current stock price of $210.</p>\n<p><b>Risks to Assumptions</b></p>\n<p>Now, it’s obviously baffling to watch how Mr. Market has decided to discount BABA to such an extent as if the company has lost all its key sources of growth, when in fact there is still so much potential upside coming from its commerce segment, the new marketplace initiatives and its growing Ali Cloud segment, among others. The main realistic reason that we identified for the stock's underperformance would simply be regulatory risk. We think investors should acknowledge that this risk is very real and at times huge Chinese companies have found themselves to be subjected to extra scrutiny (which is nothing new in fact) by the Chinese government. What’s critical here is that the Chinese government seemingly has significant clout over the behavior and actions of their tech behemoths that at times may be largely unpredictable. The market certainly hates unpredictability and therefore they may have significantly discounted BABA as a result of that. If investors are not able to handle uncertainty with regard to potentially unpredictable regulatory actions and their aftermath, then BABA may not be appropriate for you. However, if you believe that this is just a blip in BABA’s long journey, then you would surely find BABA's valuations extremely attractive right now, coupled with a long term mindset.</p>\n<p><b>Wrapping It All Up</b></p>\n<p>Alibaba has continued to deliver solid results that demonstrated the strong capability of the company to execute well. As the company continues to operate within a market with so many growth drivers that are expected to drive the company’s future growth, investors should find the current valuations highly attractive.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba Stock: The Bottoming Process Looks To Be Forming Already</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba Stock: The Bottoming Process Looks To Be Forming Already\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 09:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4435297-alibaba-stock-bottoming-process-forming-buy-now><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nAlibaba is probably the most undervalued growth stock right now.\nThe company’s multiple growth drivers within a rapidly expanding market made its valuations look even more baffling.\nThe short...</p>\n\n<a href=\"https://seekingalpha.com/article/4435297-alibaba-stock-bottoming-process-forming-buy-now\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","09988":"阿里巴巴-W"},"source_url":"https://seekingalpha.com/article/4435297-alibaba-stock-bottoming-process-forming-buy-now","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175693382","content_text":"Summary\n\nAlibaba is probably the most undervalued growth stock right now.\nThe company’s multiple growth drivers within a rapidly expanding market made its valuations look even more baffling.\nThe short term technical picture may be turning bullish with a potential double bottom price action signal.\nWe discuss the company’s multiple growth drivers and let investors judge for themselves.\n\nYongyuan Dai/iStock Unreleased via Getty Images\nThe Technical Thesis\nSource: TradingView\nAlibaba’s stock price has endured a terrible 8 months ever since its Ant Financial IPO was pulled in early Nov 20, with the stock languishing in the doldrums 34% off its high. When considering the health of its long term uptrend, it’s clear that BABA has a relatively strong uptrend bias and has generally been well supported along its key 50W MA. The only other time in the last 4 years that it lost its key 50W MA support level was during the 2018 bear market where BABA dropped about 40%, but was still well supported above the important 200W MA, which we usually consider as the “last line of defense”. Right now BABA is somewhat facing a similar situation again: down 34%, lost the 50W MA, but looks to be well supported above the 200W MA. In addition to that, one interesting observation in price action analysis may lead price action traders/investors to be especially bullish: a potential double bottom formation. BABA's price is seemingly going through a double bottom like it did during the 2018 bear market before it rallied strongly thereafter. As a result, BABA’s current level may offer a possible technical buy entry point now.\nBABA's Fundamental Thesis: Rapidly Expanding Growth Drivers\nAnnual GMV. Data source: Company filings\nAnnual e-commerce revenue. Data source: Company filings\nBABA’s GMV grew from 1.68T yuan to 7.49T yuan in just a matter of 7 years, which represented a CAGR of 23.8%, a truly amazing growth rate. We also saw its GMV growth being converted into revenue growth as its China commerce revenue grew from 7.67B yuan to 473.68B yuan, at a CAGR of 51% over the last 10 years. While its international footprint remains considerably smaller, it still grew at a CAGR of 30.42% over the last 10 years, which was by no means slow.\nEven though China’s e-commerce market is expected to grow considerably slower at a CAGR of 12.4% over the next three years, from 13.8T yuan, equivalent to $2.16T in 2021 to 19.6T yuan,equivalent to $3.06T by 2024, the massive size of the market still offers tremendous upside potential for BABA and its closest competitors to grow into.\nE-commerce revenue in the U.S. Data source: Statista\nWhen we take things into clearer perspective by comparing China’s growth rate and size of its market to that of the U.S. e-commerce market, we could see the huge differences in their sizes and growth rates as the U.S. e-commerce market is only expected to grow at a CAGR of 4.67% from 2021 to 2025, which is significantly slower than China’s 12.4%. In addition, the U.S. market is also expected to reach about $563B in total revenue, which is 18% of what the China market is expected to be worth by then.\nPeers EBIT Margin and Projected EBIT Margin. Data source: S&P Capital IQ\nEven though Alibaba has been facing increased competitive pressures from its fast growing key competitors: JD.com(NASDAQ:JD)and Pinduoduo(NASDAQ:PDD), BABA has already been operating a much more profitable business (both EBIT and FCF), and is expected to continue delivering strong profitability moving forward, which should give the company tremendous flexibility to compete head on with JD and PDD in its quest to extend its leadership. Investors may observe that BABA’s EBIT margin was affected by the one-off administrative penalty of $2,782M that was reflected in its SG&A, and therefore skewed its EBIT margin to the downside.\nOne important move was the company’s decision to further its investment in the Community Marketplace, which is PDD’s main e-commerce strategy that saw PDD gain a total of 823M AAC in its latest quarter as compared to BABA’s 891M AAC. PDD’s AAC growth is truly phenomenal considering it had only 100M AAC in Q2’C17 as compared to BABA’s 466M AAC in the same period.\nTherefore, the momentum of growth has surely swung over to the Community Marketplace segment and BABA would need to pull out its big guns (which it has) to compete for dominance with PDD and JD.\nMarket size of community group buying in China. Data source: iiMedia Research\nEven though the expected total market size of 102B yuan by 2022 represented only about 21.5% of BABA’s FY 21 China commerce revenue, the expected rapid CAGR of 44.22% over 3 years from 2019 to 2022 cannot be missed by BABA. Although the market is still relatively small, BABA cannot allow the current leader in this market: PDD to so easily dominate and gobble up the early high growth rates at the ignorance of everyone else. Certainly BABA must compete and fight for its place in this segment and strive for early leadership to prevent PDD from extending its lead.\nPDD profitability metrics & revenue growth forecast. Data source: S&P Capital IQ\nWe could observe from the above chart that PDD is expected to continue growing its revenue rapidly over the next few years, even though they are expected to normalize subsequently. More importantly, PDD is also expected to increasingly improve its EBIT and FCF profitability moving forward. This shows that the Community Marketplace segment is an highly important growth driver that BABA must use its strength to exploit in order to deny PDD’s claim to undisputed leadership so early on in the game.\nChina public cloud spending. Source:China Internet Watch; Canalys\nSize of China public cloud market. Data source: CAICT; Sina.com.cn\nBABA has a 40% share in China’s public cloud market, way ahead of its key competitors. However, it’s important to note that despite this leadership, BABA is still in heavy investment mode to continue growing its market share as China’s public cloud market is expected to grow from 26.48B yuan in 2017 to 230.74B yuan by 2023, which would represent a CAGR of 43.4%, an incredibly stellar growth rate. This is especially clear when we compare China’s growth rate to the worldwide growth rate (see below) as public cloud spending worldwide is expected to grow from $145B in 2017 to $397B by 2022, that would represent a CAGR of 22.3%.\nWorldwide public cloud spending. Data source: Gartner\nWorldwide public cloud market share. Source:CnTechPost; Gartner\nTherefore, I don’t find it surprising that Ali Cloud has continued to extend its lead over Alphabet’s(NASDAQ:GOOGL)(NASDAQ:GOOG)GCP with a market share of 9.5% in 2020. While AMZN remains the clear leader in the market, its market share has been coming down considerably as public cloud spending continues to expand, indicating that there is a huge potential for growth for multiple players to exist. With BABA’s leadership in the rapidly expanding Chinese market, I’m increasingly bullish on the future profit and FCF contribution from this segment to BABA’s performance over time. Although BABA’s cloud segment has not been EBIT profitable yet (FY 21 EBIT margin: -15%, FY 20 EBIT margin: -17.5%), it’s also useful to note that GCP has also not been profitable for Alphabet as well (FY 20 EBIT margin: -42.9%, FY 19 EBIT margin: -52%). Therefore, we need to give BABA some time to scale up its cloud services in APAC and in China where it is expected to have stronger leadership to allow it to grow faster and investors should expect this to be a highly profitable segment over time.\nBABA's Valuations Look Highly Compelling\nNTM TEV / EBIT 3Y range.\nEV / Fwd EBIT and EV / Fwd Rev trend. Data source: S&P Capital IQ\nWhen we consider BABA's TEV / EBIT historical range, where the 3Y mean read 33.54x, BABA’s EV / Fwd EBIT trend certainly imply a hugely undervalued stock as BABA is still expected to grow its revenue and operating profits rapidly. However, as we wanted to obtain greater clarity over how its counterparts are also valued, we thought it would be useful if we value BABA’s EBIT over a set of benchmark companies that is presented below.\nPeers EV / EBIT Valuations. Data source: S&P Capital IQ\nBy using a blend of historical and forward EBIT, we could see that BABA’s EV / EBIT really looks undervalued when compared to the median value of the set of observed values from the benchmark companies. We derived a fair value range for BABA of $294.98 at the midpoint of the range, that represented a potential upside of 40.5% based on the current stock price of $210.\nRisks to Assumptions\nNow, it’s obviously baffling to watch how Mr. Market has decided to discount BABA to such an extent as if the company has lost all its key sources of growth, when in fact there is still so much potential upside coming from its commerce segment, the new marketplace initiatives and its growing Ali Cloud segment, among others. The main realistic reason that we identified for the stock's underperformance would simply be regulatory risk. We think investors should acknowledge that this risk is very real and at times huge Chinese companies have found themselves to be subjected to extra scrutiny (which is nothing new in fact) by the Chinese government. What’s critical here is that the Chinese government seemingly has significant clout over the behavior and actions of their tech behemoths that at times may be largely unpredictable. The market certainly hates unpredictability and therefore they may have significantly discounted BABA as a result of that. If investors are not able to handle uncertainty with regard to potentially unpredictable regulatory actions and their aftermath, then BABA may not be appropriate for you. However, if you believe that this is just a blip in BABA’s long journey, then you would surely find BABA's valuations extremely attractive right now, coupled with a long term mindset.\nWrapping It All Up\nAlibaba has continued to deliver solid results that demonstrated the strong capability of the company to execute well. As the company continues to operate within a market with so many growth drivers that are expected to drive the company’s future growth, investors should find the current valuations highly attractive.","news_type":1},"isVote":1,"tweetType":1,"viewCount":582,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":116347083,"gmtCreate":1622777184442,"gmtModify":1704190998299,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Woo","listText":"Woo","text":"Woo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/116347083","repostId":"2140026421","repostType":4,"repost":{"id":"2140026421","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1622775272,"share":"https://ttm.financial/m/news/2140026421?lang=&edition=fundamental","pubTime":"2021-06-04 10:54","market":"hk","language":"en","title":"Here's AMC's blunt new warning to prospective buyers of its new stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2140026421","media":"Dow Jones","summary":"AMC Entertainment Holdings on Thursday announced a new stock sale to take advantage of the extraordi","content":"<p>AMC Entertainment Holdings on Thursday announced a new stock sale to take advantage of the extraordinary retail interest that has driven the movie-theater chain's equity up by 2,850% this year.</p><p>AMC's <a href=\"https://laohu8.com/S/AMC\">$(AMC)$</a> lawyers are apparently as surprised as anyone -- so much so that the company added a fresh risk factor to its 11 million--share sale, which basically boils down to this warning: Prepare to lose everything if you buy the stock.</p><p>The following is the full, extraordinary warning (bolded and italicized text reproduced as in AMC prospectus):</p><p>The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses.</p><p>The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses. For example, during 2021 to date, the market price of our Class A common stock has fluctuated from an intra-day low of $1.91 per share on January 5, 2021 to an intra-day high on the NYSE of $72.62 on June 2, 2021 and the last reported sale price of our Class A common stock on the NYSE on June 2, 2021, was $62.55 per share. During 2021 to date, daily trading volume ranged from approximately 23,598,228 to 1,253,253,550 shares. Within the last seven business days, the market price of our Class A common stock has fluctuated from an intra-day low of $12.18 on May 24, 2021 to an intra-day high of $72.62 on June 2, 2021, and we have made no disclosure regarding a change to our underlying business during that period, other than with respect to an additional financing.</p><p>We believe that the recent volatility and our current market prices reflect market and trading dynamics unrelated to our underlying business, or macro or industry fundamentals, and we do not know how long these dynamics will last. Under the circumstances, we caution you against investing in our Class A common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.</p><p>Extreme fluctuations in the market price of our Class A common stock have been accompanied by reports of strong and atypical retail investor interest, including on social media and online forums. The market volatility and trading patterns we have experienced create several risks for investors, including the following:</p><ul><li>the market price of our Class A common stock has experienced and may continue to experience rapid and substantial increases or decreases unrelated to our operating performance or prospects, or macro or industry fundamentals, and substantial increases may be significantly inconsistent with the risks and uncertainties that we continue to face;</li><li>factors in the public trading market for our Class A common stock include the sentiment of retail investors (including as may be expressed on financial trading and other social media sites and online forums), the direct access by retail investors to broadly available trading platforms, the amount and status of short interest in our securities, access to margin debt, trading in options and other derivatives on our Class A common stock and any related hedging and other trading factors;</li><li>our market capitalization, as implied by various trading prices, currently reflects valuations that diverge significantly from those seen prior to recent volatility and that are significantly higher than our market capitalization immediately prior to the COVID-19 pandemic, and to the extent these valuations reflect trading dynamics unrelated to our financial performance or prospects, purchasers of our Class A common stock could incur substantial losses if there are declines in market prices driven by a return to earlier valuations;</li><li>to the extent volatility in our Class A common stock is caused, as has widely been reported, by a “short squeeze” in which coordinated trading activity causes a spike in the market price of our Class A common stock as traders with a short position make market purchases to avoid or to mitigate potential losses, investors purchase at inflated prices unrelated to our financial performance or prospects, and may thereafter suffer substantial losses as prices decline once the level of short-covering purchases has abated; and</li><li>if the market price of our Class A common stock declines, you may be unable to resell your shares at or above the price at which you acquired them. We cannot assure you that the equity issuance of our Class A common stock will not fluctuate or decline significantly in the future, in which case you could incur substantial losses.</li></ul><p>We may continue to incur rapid and substantial increases or decreases in our stock price in the foreseeable future that may not coincide in timing with the disclosure of news or developments by or affecting us. Accordingly, the market price of our shares of Class A common stock may fluctuate dramatically, and may decline rapidly, regardless of any developments in our business.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's AMC's blunt new warning to prospective buyers of its new stock offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's AMC's blunt new warning to prospective buyers of its new stock offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-04 10:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMC Entertainment Holdings on Thursday announced a new stock sale to take advantage of the extraordinary retail interest that has driven the movie-theater chain's equity up by 2,850% this year.</p><p>AMC's <a href=\"https://laohu8.com/S/AMC\">$(AMC)$</a> lawyers are apparently as surprised as anyone -- so much so that the company added a fresh risk factor to its 11 million--share sale, which basically boils down to this warning: Prepare to lose everything if you buy the stock.</p><p>The following is the full, extraordinary warning (bolded and italicized text reproduced as in AMC prospectus):</p><p>The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses.</p><p>The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses. For example, during 2021 to date, the market price of our Class A common stock has fluctuated from an intra-day low of $1.91 per share on January 5, 2021 to an intra-day high on the NYSE of $72.62 on June 2, 2021 and the last reported sale price of our Class A common stock on the NYSE on June 2, 2021, was $62.55 per share. During 2021 to date, daily trading volume ranged from approximately 23,598,228 to 1,253,253,550 shares. Within the last seven business days, the market price of our Class A common stock has fluctuated from an intra-day low of $12.18 on May 24, 2021 to an intra-day high of $72.62 on June 2, 2021, and we have made no disclosure regarding a change to our underlying business during that period, other than with respect to an additional financing.</p><p>We believe that the recent volatility and our current market prices reflect market and trading dynamics unrelated to our underlying business, or macro or industry fundamentals, and we do not know how long these dynamics will last. Under the circumstances, we caution you against investing in our Class A common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.</p><p>Extreme fluctuations in the market price of our Class A common stock have been accompanied by reports of strong and atypical retail investor interest, including on social media and online forums. The market volatility and trading patterns we have experienced create several risks for investors, including the following:</p><ul><li>the market price of our Class A common stock has experienced and may continue to experience rapid and substantial increases or decreases unrelated to our operating performance or prospects, or macro or industry fundamentals, and substantial increases may be significantly inconsistent with the risks and uncertainties that we continue to face;</li><li>factors in the public trading market for our Class A common stock include the sentiment of retail investors (including as may be expressed on financial trading and other social media sites and online forums), the direct access by retail investors to broadly available trading platforms, the amount and status of short interest in our securities, access to margin debt, trading in options and other derivatives on our Class A common stock and any related hedging and other trading factors;</li><li>our market capitalization, as implied by various trading prices, currently reflects valuations that diverge significantly from those seen prior to recent volatility and that are significantly higher than our market capitalization immediately prior to the COVID-19 pandemic, and to the extent these valuations reflect trading dynamics unrelated to our financial performance or prospects, purchasers of our Class A common stock could incur substantial losses if there are declines in market prices driven by a return to earlier valuations;</li><li>to the extent volatility in our Class A common stock is caused, as has widely been reported, by a “short squeeze” in which coordinated trading activity causes a spike in the market price of our Class A common stock as traders with a short position make market purchases to avoid or to mitigate potential losses, investors purchase at inflated prices unrelated to our financial performance or prospects, and may thereafter suffer substantial losses as prices decline once the level of short-covering purchases has abated; and</li><li>if the market price of our Class A common stock declines, you may be unable to resell your shares at or above the price at which you acquired them. We cannot assure you that the equity issuance of our Class A common stock will not fluctuate or decline significantly in the future, in which case you could incur substantial losses.</li></ul><p>We may continue to incur rapid and substantial increases or decreases in our stock price in the foreseeable future that may not coincide in timing with the disclosure of news or developments by or affecting us. Accordingly, the market price of our shares of Class A common stock may fluctuate dramatically, and may decline rapidly, regardless of any developments in our business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140026421","content_text":"AMC Entertainment Holdings on Thursday announced a new stock sale to take advantage of the extraordinary retail interest that has driven the movie-theater chain's equity up by 2,850% this year.AMC's $(AMC)$ lawyers are apparently as surprised as anyone -- so much so that the company added a fresh risk factor to its 11 million--share sale, which basically boils down to this warning: Prepare to lose everything if you buy the stock.The following is the full, extraordinary warning (bolded and italicized text reproduced as in AMC prospectus):The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses.The market prices and trading volume of our shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Class A common stock to incur substantial losses. For example, during 2021 to date, the market price of our Class A common stock has fluctuated from an intra-day low of $1.91 per share on January 5, 2021 to an intra-day high on the NYSE of $72.62 on June 2, 2021 and the last reported sale price of our Class A common stock on the NYSE on June 2, 2021, was $62.55 per share. During 2021 to date, daily trading volume ranged from approximately 23,598,228 to 1,253,253,550 shares. Within the last seven business days, the market price of our Class A common stock has fluctuated from an intra-day low of $12.18 on May 24, 2021 to an intra-day high of $72.62 on June 2, 2021, and we have made no disclosure regarding a change to our underlying business during that period, other than with respect to an additional financing.We believe that the recent volatility and our current market prices reflect market and trading dynamics unrelated to our underlying business, or macro or industry fundamentals, and we do not know how long these dynamics will last. Under the circumstances, we caution you against investing in our Class A common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.Extreme fluctuations in the market price of our Class A common stock have been accompanied by reports of strong and atypical retail investor interest, including on social media and online forums. The market volatility and trading patterns we have experienced create several risks for investors, including the following:the market price of our Class A common stock has experienced and may continue to experience rapid and substantial increases or decreases unrelated to our operating performance or prospects, or macro or industry fundamentals, and substantial increases may be significantly inconsistent with the risks and uncertainties that we continue to face;factors in the public trading market for our Class A common stock include the sentiment of retail investors (including as may be expressed on financial trading and other social media sites and online forums), the direct access by retail investors to broadly available trading platforms, the amount and status of short interest in our securities, access to margin debt, trading in options and other derivatives on our Class A common stock and any related hedging and other trading factors;our market capitalization, as implied by various trading prices, currently reflects valuations that diverge significantly from those seen prior to recent volatility and that are significantly higher than our market capitalization immediately prior to the COVID-19 pandemic, and to the extent these valuations reflect trading dynamics unrelated to our financial performance or prospects, purchasers of our Class A common stock could incur substantial losses if there are declines in market prices driven by a return to earlier valuations;to the extent volatility in our Class A common stock is caused, as has widely been reported, by a “short squeeze” in which coordinated trading activity causes a spike in the market price of our Class A common stock as traders with a short position make market purchases to avoid or to mitigate potential losses, investors purchase at inflated prices unrelated to our financial performance or prospects, and may thereafter suffer substantial losses as prices decline once the level of short-covering purchases has abated; andif the market price of our Class A common stock declines, you may be unable to resell your shares at or above the price at which you acquired them. We cannot assure you that the equity issuance of our Class A common stock will not fluctuate or decline significantly in the future, in which case you could incur substantial losses.We may continue to incur rapid and substantial increases or decreases in our stock price in the foreseeable future that may not coincide in timing with the disclosure of news or developments by or affecting us. Accordingly, the market price of our shares of Class A common stock may fluctuate dramatically, and may decline rapidly, regardless of any developments in our business.","news_type":1},"isVote":1,"tweetType":1,"viewCount":461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183257494,"gmtCreate":1623333828518,"gmtModify":1704201156974,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Lnc","listText":"Lnc","text":"Lnc","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/183257494","repostId":"1106213554","repostType":4,"repost":{"id":"1106213554","pubTimestamp":1623332534,"share":"https://ttm.financial/m/news/1106213554?lang=&edition=fundamental","pubTime":"2021-06-10 21:42","market":"us","language":"en","title":"S&P 500 rises to new record, shaking off inflation fears","url":"https://stock-news.laohu8.com/highlight/detail?id=1106213554","media":"cnbc","summary":"The S&P 500 climbed to an all-time high on Thursday as investors shrugged off a key inflation report","content":"<div>\n<p>The S&P 500 climbed to an all-time high on Thursday as investors shrugged off a key inflation report that showed a bigger-than-expected increase in price pressures.\nThe broad equity benchmark rose ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/09/stock-market-open-to-close-news.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 rises to new record, shaking off inflation fears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 rises to new record, shaking off inflation fears\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-10 21:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/09/stock-market-open-to-close-news.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 climbed to an all-time high on Thursday as investors shrugged off a key inflation report that showed a bigger-than-expected increase in price pressures.\nThe broad equity benchmark rose ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/09/stock-market-open-to-close-news.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"source_url":"https://www.cnbc.com/2021/06/09/stock-market-open-to-close-news.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1106213554","content_text":"The S&P 500 climbed to an all-time high on Thursday as investors shrugged off a key inflation report that showed a bigger-than-expected increase in price pressures.\nThe broad equity benchmark rose 0.6% to hit an intraday record of 4,246.20, overtaking its May 7 high after the market traded sideways for a month. The Dow Jones Industrial Average advanced 275 points, while the Nasdaq Composite traded 0.2% higher even with bond yields rising.\nConsumer prices for May accelerated at their fastest pace since the summer of 2008 amid the economic recovery from the pandemic-triggered recession,the Labor Department reported Thursday.\nThe consumer price index, which represents a basket including food, energy, groceries across a spectrum of goods, rose 5% from a year ago. Economists surveyed by Dow Jones had been expecting a gain of 4.7%.\nFears of spiking inflation have weighed on the stock market in the last month, with investors worried the jump in prices will raise costs for companies, spark a move higher in interest rates and cause the Federal Reserve to remove its easy money policies.\n“This CPI isn’t likely to change the narrative dramatically and there are still indications that inflation momentum is set to abate in the coming months,” Adam Crisafulli, founder of Vital Knowledge, said in a note Thursday.\nMany economists also said the surge in used car costs for the month could have skewed the inflation reading. Used car and truck prices jumped more than 7%, accounting for one-third of the total increase for the month, according to the BLS. The jump in used car prices likely reflects a temporary phenomenon related to the pandemic and auto supply.\nUPS shares rose about 1% in premarket trading afteran upgrade from JPMorgan. Shares of Boeing and Delta Air Lines were also higher in premarket trading.\nU.S. markets continued to trade within a tight range on Wednesday, with all three major indexes ending the day within 0.5% of Tuesday’s closing levels. The Dow, S&P 500 and Nasdaq Composite all fell during regular trading, ending the session further away from their respective all-time highs.\nThe S&P 500 remains closest to its benchmark and is just 0.44% away from a new all-time high. The Dow and Nasdaq are roughly 2% away from records.\nVideo-game retailer and meme stockGameStopfell 7% in premarket trading even after the company tapped formerAmazon executive Matt Furlong to be its next CEOand said that sales rose 25% last quarter. The company also said it may sell up to 5 million additional shares.","news_type":1},"isVote":1,"tweetType":1,"viewCount":623,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188052503,"gmtCreate":1623417708202,"gmtModify":1704203059698,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Likes","listText":"Likes","text":"Likes","images":[{"img":"https://static.tigerbbs.com/502a995361f770610b850e5da688999c","width":"1080","height":"2070"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/188052503","isVote":1,"tweetType":1,"viewCount":411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":119188360,"gmtCreate":1622527221550,"gmtModify":1704185667602,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Tesla","listText":"Tesla","text":"Tesla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/119188360","repostId":"1133436315","repostType":4,"repost":{"id":"1133436315","pubTimestamp":1622511921,"share":"https://ttm.financial/m/news/1133436315?lang=&edition=fundamental","pubTime":"2021-06-01 09:45","market":"hk","language":"en","title":"Elon Musk Thinks This Is A 'Great Idea' To Utilize Energy Generated During Dogecoin Mining","url":"https://stock-news.laohu8.com/highlight/detail?id=1133436315","media":"Benzinga","summary":"Tesla Inc.(NASDAQ:TSLA) CEO Elon Musk on Saturday backed a proposition from Blockfolio on how to uti","content":"<p><b>Tesla Inc.</b>(NASDAQ:TSLA) CEO Elon Musk on Saturday backed a proposition from Blockfolio on how to utilize energy generated during the process of<b>Dogecoin</b>(DOGE) mining.</p>\n<p><b>What Happened:</b>Blockfolio in a tweet proposed<b>“</b>a hot tub that's heated by mining dogecoin,” which Musk dubbed a “great idea.”</p>\n<p>The cryptocurrency exchange and portfolio tracking service provider called on Elon Musk to “just make it happen” no matter how.<img src=\"https://static.tigerbbs.com/3f6b1e5bd58956d6d579a1f9cebcd1ef\" tg-width=\"551\" tg-height=\"254\" referrerpolicy=\"no-referrer\">Among others responding to the tweet, Dogecoin co-creator Billy Markus noted the high amount of heat generated when he used to mine the meme cryptocurrency.</p>\n<p>“When I used to mine, [I] definitely didn’t need a heater anymore,” Markus said. “Only problem was that hardware burning smell.”</p>\n<p>Some other users also noted the high amount of noise that is generated with some of the mining hardware.</p>\n<p><b>Why It Matters:</b>Musk has come intensely in support of Dogecoin over the past year and half, primarily citing its origin and existence as a meme as the basis of his support.</p>\n<p>Tesla announced itwould stopaccepting<b>Bitcoin</b>(BTC) as a form of payment, earlier this month, citing environmental concerns related to the mining of the apex cryptocurrency.</p>\n<p>Musk followed up with an announcement that he was working with Dogecoin developers andcalled for helpfrom his followers on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a>.</p>\n<p>Dogecoin utilizes the scrypt proof-of-work algorithm against the SHA-256 algorithm utilized by Bitcoin, making it relatively more feasible to mine for individuals on their personal devices.</p>\n<p>Musk, last week, also suggested he was taking a more nuanced approach towards the environmental concerns of Bitcoin&nbsp;mining, dubbing his talks with North <a href=\"https://laohu8.com/S/AFG\">American</a> Bitcoin miners as “potentially promising.”</p>\n<p><b>Price Action:</b>Dogecoin traded 0.96% higher over 24 hours at press time at $0.3086. Bitcoin traded 2.9% higher at $36,817.17.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elon Musk Thinks This Is A 'Great Idea' To Utilize Energy Generated During Dogecoin Mining</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElon Musk Thinks This Is A 'Great Idea' To Utilize Energy Generated During Dogecoin Mining\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 09:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/cryptocurrency/21/05/21355896/elon-musk-thinks-this-is-a-great-idea-to-utilize-energy-generated-during-dogecoin-mining><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla Inc.(NASDAQ:TSLA) CEO Elon Musk on Saturday backed a proposition from Blockfolio on how to utilize energy generated during the process ofDogecoin(DOGE) mining.\nWhat Happened:Blockfolio in a ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/05/21355896/elon-musk-thinks-this-is-a-great-idea-to-utilize-energy-generated-during-dogecoin-mining\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.benzinga.com/markets/cryptocurrency/21/05/21355896/elon-musk-thinks-this-is-a-great-idea-to-utilize-energy-generated-during-dogecoin-mining","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133436315","content_text":"Tesla Inc.(NASDAQ:TSLA) CEO Elon Musk on Saturday backed a proposition from Blockfolio on how to utilize energy generated during the process ofDogecoin(DOGE) mining.\nWhat Happened:Blockfolio in a tweet proposed“a hot tub that's heated by mining dogecoin,” which Musk dubbed a “great idea.”\nThe cryptocurrency exchange and portfolio tracking service provider called on Elon Musk to “just make it happen” no matter how.Among others responding to the tweet, Dogecoin co-creator Billy Markus noted the high amount of heat generated when he used to mine the meme cryptocurrency.\n“When I used to mine, [I] definitely didn’t need a heater anymore,” Markus said. “Only problem was that hardware burning smell.”\nSome other users also noted the high amount of noise that is generated with some of the mining hardware.\nWhy It Matters:Musk has come intensely in support of Dogecoin over the past year and half, primarily citing its origin and existence as a meme as the basis of his support.\nTesla announced itwould stopacceptingBitcoin(BTC) as a form of payment, earlier this month, citing environmental concerns related to the mining of the apex cryptocurrency.\nMusk followed up with an announcement that he was working with Dogecoin developers andcalled for helpfrom his followers on Twitter.\nDogecoin utilizes the scrypt proof-of-work algorithm against the SHA-256 algorithm utilized by Bitcoin, making it relatively more feasible to mine for individuals on their personal devices.\nMusk, last week, also suggested he was taking a more nuanced approach towards the environmental concerns of Bitcoin mining, dubbing his talks with North American Bitcoin miners as “potentially promising.”\nPrice Action:Dogecoin traded 0.96% higher over 24 hours at press time at $0.3086. Bitcoin traded 2.9% higher at $36,817.17.","news_type":1},"isVote":1,"tweetType":1,"viewCount":535,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119188724,"gmtCreate":1622527253568,"gmtModify":1704185668259,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Tesla","listText":"Tesla","text":"Tesla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/119188724","repostId":"2140545174","repostType":4,"repost":{"id":"2140545174","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622506410,"share":"https://ttm.financial/m/news/2140545174?lang=&edition=fundamental","pubTime":"2021-06-01 08:13","market":"us","language":"en","title":"Tesla's vehicle price increases due to supply chain pressure, Musk says","url":"https://stock-news.laohu8.com/highlight/detail?id=2140545174","media":"Reuters","summary":"May 31 (Reuters) - The price of Tesla vehicles is increasing due to supply chain pressures across th","content":"<p>May 31 (Reuters) - The price of Tesla vehicles is increasing due to supply chain pressures across the auto industry, particularly for raw materials, Elon Musk said on Monday in response to a tweet</p>\n<p>\"Prices increasing due to major supply chain price pressure industry-wide. Raw materials especially,\" Musk said in a tweet.</p>\n<p>He was responding to an unverified <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> account called @Ryanth3nerd, which said, \"I really don't like the direction @tesla is going raising prices of vehicles but removing features like lumbar for the Model Y...\"</p>\n<p>In May, Tesla increased its Model 3 and Model Y prices, the automaker's fifth incremental price increase for its vehicles in just a few months, the Electrek website reported</p>\n<p>During an an earnings conference call in April, Musk said Tesla had experienced \"some of the most difficult supply chain challenges,\" citing a chip shortage. \"We're mostly out of that particular problem,\" he added at the time.</p>\n<p>In response to the removal of lumbar support on the passenger side in Tesla's Model Y, Musk said, \"Moving lumbar was removed only in front passenger seat of 3/Y (obv not there in rear seats). Logs showed almost no usage. Not worth cost/mass for everyone when almost never used.\"</p>\n<p>Earlier on Monday, the Electrek reported</p>\n<p>that new Tesla Model Y owners are reporting that their electric SUVs are being delivered without lumbar support on the passenger side.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla's vehicle price increases due to supply chain pressure, Musk says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla's vehicle price increases due to supply chain pressure, Musk says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-01 08:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>May 31 (Reuters) - The price of Tesla vehicles is increasing due to supply chain pressures across the auto industry, particularly for raw materials, Elon Musk said on Monday in response to a tweet</p>\n<p>\"Prices increasing due to major supply chain price pressure industry-wide. Raw materials especially,\" Musk said in a tweet.</p>\n<p>He was responding to an unverified <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> account called @Ryanth3nerd, which said, \"I really don't like the direction @tesla is going raising prices of vehicles but removing features like lumbar for the Model Y...\"</p>\n<p>In May, Tesla increased its Model 3 and Model Y prices, the automaker's fifth incremental price increase for its vehicles in just a few months, the Electrek website reported</p>\n<p>During an an earnings conference call in April, Musk said Tesla had experienced \"some of the most difficult supply chain challenges,\" citing a chip shortage. \"We're mostly out of that particular problem,\" he added at the time.</p>\n<p>In response to the removal of lumbar support on the passenger side in Tesla's Model Y, Musk said, \"Moving lumbar was removed only in front passenger seat of 3/Y (obv not there in rear seats). Logs showed almost no usage. Not worth cost/mass for everyone when almost never used.\"</p>\n<p>Earlier on Monday, the Electrek reported</p>\n<p>that new Tesla Model Y owners are reporting that their electric SUVs are being delivered without lumbar support on the passenger side.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140545174","content_text":"May 31 (Reuters) - The price of Tesla vehicles is increasing due to supply chain pressures across the auto industry, particularly for raw materials, Elon Musk said on Monday in response to a tweet\n\"Prices increasing due to major supply chain price pressure industry-wide. Raw materials especially,\" Musk said in a tweet.\nHe was responding to an unverified Twitter account called @Ryanth3nerd, which said, \"I really don't like the direction @tesla is going raising prices of vehicles but removing features like lumbar for the Model Y...\"\nIn May, Tesla increased its Model 3 and Model Y prices, the automaker's fifth incremental price increase for its vehicles in just a few months, the Electrek website reported\nDuring an an earnings conference call in April, Musk said Tesla had experienced \"some of the most difficult supply chain challenges,\" citing a chip shortage. \"We're mostly out of that particular problem,\" he added at the time.\nIn response to the removal of lumbar support on the passenger side in Tesla's Model Y, Musk said, \"Moving lumbar was removed only in front passenger seat of 3/Y (obv not there in rear seats). Logs showed almost no usage. Not worth cost/mass for everyone when almost never used.\"\nEarlier on Monday, the Electrek reported\nthat new Tesla Model Y owners are reporting that their electric SUVs are being delivered without lumbar support on the passenger side.","news_type":1},"isVote":1,"tweetType":1,"viewCount":491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":138504516,"gmtCreate":1621947871935,"gmtModify":1704364932386,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Like &amp; comm","listText":"Like &amp; comm","text":"Like & comm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/138504516","repostId":"2138167226","repostType":4,"repost":{"id":"2138167226","pubTimestamp":1621946580,"share":"https://ttm.financial/m/news/2138167226?lang=&edition=fundamental","pubTime":"2021-05-25 20:43","market":"us","language":"en","title":"Tesla launches China data centre to store data locally","url":"https://stock-news.laohu8.com/highlight/detail?id=2138167226","media":"StreetInsider","summary":"BEIJING (Reuters) -     U.S. electric vehicle maker Tesla Inc said on Tuesday it has established a d","content":"<p>BEIJING (Reuters) -     U.S. electric vehicle maker Tesla Inc said on Tuesday it has established a data centre in China to store car data locally.</p><p>Tesla said in a Weibo post that data generated by all cars it sells in China, where it is making Model 3 sedans and Model Y sport-utility vehicles, will be stored locally.</p><p>Tesla would try to ensure the safety of the data in China, it said.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla launches China data centre to store data locally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla launches China data centre to store data locally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 20:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18469726><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BEIJING (Reuters) -     U.S. electric vehicle maker Tesla Inc said on Tuesday it has established a data centre in China to store car data locally.Tesla said in a Weibo post that data generated by all ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18469726\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAAS":"中汽系统","TSLA":"特斯拉"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18469726","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138167226","content_text":"BEIJING (Reuters) -     U.S. electric vehicle maker Tesla Inc said on Tuesday it has established a data centre in China to store car data locally.Tesla said in a Weibo post that data generated by all cars it sells in China, where it is making Model 3 sedans and Model Y sport-utility vehicles, will be stored locally.Tesla would try to ensure the safety of the data in China, it said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119183707,"gmtCreate":1622527172009,"gmtModify":1704185664968,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119183707","repostId":"1133436315","repostType":4,"isVote":1,"tweetType":1,"viewCount":617,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119183019,"gmtCreate":1622527112131,"gmtModify":1704185663812,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Like &amp; comm","listText":"Like &amp; comm","text":"Like & comm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119183019","repostId":"2139304437","repostType":4,"repost":{"id":"2139304437","pubTimestamp":1622513653,"share":"https://ttm.financial/m/news/2139304437?lang=&edition=fundamental","pubTime":"2021-06-01 10:14","market":"us","language":"en","title":"Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2139304437","media":"Motley Fool","summary":"Even a modest investment in these unstoppable stocks could reap huge rewards over the next decade.","content":"<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad <a href=\"https://laohu8.com/S/AONE\">one</a>.</p>\n<p>Here are two low-priced stocks that long-term investors should consider scooping up right now.</p>\n<p><img src=\"https://static.tigerbbs.com/ab4cdcd429fc79807e5230a73da31639\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h2>1. Jushi Holdings</h2>\n<p>Trading for less than $6 per share at the time of this writing, <b>Jushi Holdings</b> (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.</p>\n<p>2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.</p>\n<p>Jushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.</p>\n<p>The company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of <a href=\"https://laohu8.com/S/AONE.U\">one</a> of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.</p>\n<p>As Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.</p>\n<h2>2. <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></h2>\n<p><b>Pfizer</b> (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, <b>BioNTech </b>-- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.</p>\n<p>Pfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.</p>\n<p>During the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.</p>\n<p>In addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.</p>\n<p>Pfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHave $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 10:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISBC":"投资者银行"},"source_url":"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2139304437","content_text":"There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad one.\nHere are two low-priced stocks that long-term investors should consider scooping up right now.\n\nImage source: Getty Images.\n1. Jushi Holdings\nTrading for less than $6 per share at the time of this writing, Jushi Holdings (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.\n2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.\nJushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.\nThe company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of one of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.\nAs Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.\n2. Pfizer\nPfizer (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, BioNTech -- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.\nPfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.\nDuring the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.\nIn addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.\nPfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":505,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119189835,"gmtCreate":1622527036727,"gmtModify":1704185663159,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119189835","repostId":"2139304437","repostType":4,"repost":{"id":"2139304437","pubTimestamp":1622513653,"share":"https://ttm.financial/m/news/2139304437?lang=&edition=fundamental","pubTime":"2021-06-01 10:14","market":"us","language":"en","title":"Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2139304437","media":"Motley Fool","summary":"Even a modest investment in these unstoppable stocks could reap huge rewards over the next decade.","content":"<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad <a href=\"https://laohu8.com/S/AONE\">one</a>.</p>\n<p>Here are two low-priced stocks that long-term investors should consider scooping up right now.</p>\n<p><img src=\"https://static.tigerbbs.com/ab4cdcd429fc79807e5230a73da31639\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h2>1. Jushi Holdings</h2>\n<p>Trading for less than $6 per share at the time of this writing, <b>Jushi Holdings</b> (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.</p>\n<p>2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.</p>\n<p>Jushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.</p>\n<p>The company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of <a href=\"https://laohu8.com/S/AONE.U\">one</a> of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.</p>\n<p>As Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.</p>\n<h2>2. <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></h2>\n<p><b>Pfizer</b> (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, <b>BioNTech </b>-- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.</p>\n<p>Pfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.</p>\n<p>During the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.</p>\n<p>In addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.</p>\n<p>Pfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHave $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 10:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISBC":"投资者银行"},"source_url":"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2139304437","content_text":"There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad one.\nHere are two low-priced stocks that long-term investors should consider scooping up right now.\n\nImage source: Getty Images.\n1. Jushi Holdings\nTrading for less than $6 per share at the time of this writing, Jushi Holdings (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.\n2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.\nJushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.\nThe company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of one of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.\nAs Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.\n2. Pfizer\nPfizer (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, BioNTech -- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.\nPfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.\nDuring the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.\nIn addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.\nPfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119189074,"gmtCreate":1622527004698,"gmtModify":1704185662345,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Like &amp; comm","listText":"Like &amp; comm","text":"Like & comm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119189074","repostId":"2139304437","repostType":4,"repost":{"id":"2139304437","pubTimestamp":1622513653,"share":"https://ttm.financial/m/news/2139304437?lang=&edition=fundamental","pubTime":"2021-06-01 10:14","market":"us","language":"en","title":"Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2139304437","media":"Motley Fool","summary":"Even a modest investment in these unstoppable stocks could reap huge rewards over the next decade.","content":"<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad <a href=\"https://laohu8.com/S/AONE\">one</a>.</p>\n<p>Here are two low-priced stocks that long-term investors should consider scooping up right now.</p>\n<p><img src=\"https://static.tigerbbs.com/ab4cdcd429fc79807e5230a73da31639\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h2>1. Jushi Holdings</h2>\n<p>Trading for less than $6 per share at the time of this writing, <b>Jushi Holdings</b> (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.</p>\n<p>2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.</p>\n<p>Jushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.</p>\n<p>The company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of <a href=\"https://laohu8.com/S/AONE.U\">one</a> of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.</p>\n<p>As Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.</p>\n<h2>2. <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></h2>\n<p><b>Pfizer</b> (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, <b>BioNTech </b>-- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.</p>\n<p>Pfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.</p>\n<p>During the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.</p>\n<p>In addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.</p>\n<p>Pfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHave $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 10:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISBC":"投资者银行"},"source_url":"https://www.fool.com/investing/2021/05/31/have-500-3-absurdly-cheap-healthcare-stocks-that-l/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2139304437","content_text":"There's no shame in hunting for bargains when it comes to stocks. While a cheap per-share price in and of itself doesn't necessarily indicate that a stock is a good investment, it also doesn't mean it's a bad one.\nHere are two low-priced stocks that long-term investors should consider scooping up right now.\n\nImage source: Getty Images.\n1. Jushi Holdings\nTrading for less than $6 per share at the time of this writing, Jushi Holdings (OTC:JUSHF) is a small-cap company with serious long-term growth potential. The multistate cannabis operator owns a family of marijuana brands including Tasteology, Nira, and The Lab Concentrates. It also runs a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.\n2020 was an extremely profitable, high-growth year for Jushi Holdings. It recorded a nearly 700% spike in revenue, and its gross profits surged by a mouthwatering 760%.\nJushi Holdings reported a 30% increase in revenue during the first quarter of 2021. But the company's lightning-fast growth isn't hindering its ability to expand its cash position, as it closed the period with a robust $168 million in cash, cash equivalents, and short-term investments.\nThe company is also quickly expanding its national presence. In the month of April alone, Jushi Holdings closed its acquisition of a group of marijuana cultivation, manufacturing, and distribution facilities in Nevada and announced more pending deals that are scheduled to close later this year. In Ohio, its purchase of OhiGrow will make Jushi Holdings the owner of one of just 34 licensed cultivators in the state -- a key medical marijuana market. And in Massachusetts, where cannabis is legal for both medical and recreational purposes, Jushi plans to acquire Nature's Remedy, owner of a cultivation and manufacturing facility as well as two retail dispensaries.\nAs Jushi Holdings continues to grow its footprint in the coming years, its balance sheet and share price could also be considerably augmented. This is a great time to seize upon this premium pot stock's cheap share price to capitalize on its long-term potential.\n2. Pfizer\nPfizer (NYSE:PFE) skyrocketed to rock-star status during the pandemic when BNT162b2 -- which it developed with its German partner, BioNTech -- became the first COVID-19 vaccine to earn emergency use authorization from the U.S. Food and Drug Administration. Despite the massive success of BNT162b2, now being marketed as Comirnaty, not to mention a bulletproof portfolio of other lucrative products that have seen strong sales growth, Pfizer's shares still trade at less than $40.\nPfizer's coronavirus vaccine is already having a decisive impact on its balance sheet. The company expects to bring in about $26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it was filing with the FDA for full approval of the vaccine for use by people 16 and older.\nDuring the first quarter of 2021, Pfizer reported astonishing revenue growth of 42% year over year. But it has plenty of other products beyond its coronavirus vaccine to rely on for future gains. Even when you factor BNT162b2 out of the picture, the company still reported excellent revenue growth of 8% from the prior-year period.\nIn addition to coronavirus vaccine sales, Pfizer's robust top-line expansion during the first quarter was driven by consistent single- to double-digit percentage revenue increases across its core business segments. For example, sales in Pfizer's oncology, internal medicine, and rare disease segments shot up 16%, 10%, and 25%, respectively. Among its top-selling drugs, anticoagulant Eliquis, heart failure medications Vyndaqel and Vyndamax, and rheumatoid arthritis medication Xeljanz recorded sales gains of 25%, 88%, and 18%, respectively. Management is now forecasting full-year revenues in the range of $70.5 billion to $72.5 billion.\nPfizer's also an attractive option for dividend-seeking investors. The stock yields a healthy 4% at the time of this writing. Moreover, it trades at a mere 20 times trailing earnings. The combination of Pfizer's affordable price tag and the appealing mixture of growth and value it offers investors makes this stock a no-brainer buy in any market environment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":476,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":138504079,"gmtCreate":1621947822791,"gmtModify":1704364931555,"author":{"id":"3584575502696721","authorId":"3584575502696721","name":"PrettyNiuNiu","avatar":"https://static.tigerbbs.com/bb9c5bfe6755357f987b31cf3d35f0fc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584575502696721","authorIdStr":"3584575502696721"},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/138504079","repostId":"2138116154","repostType":4,"repost":{"id":"2138116154","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1621947600,"share":"https://ttm.financial/m/news/2138116154?lang=&edition=fundamental","pubTime":"2021-05-25 21:00","market":"us","language":"en","title":"After M&A boom via Zoom, dealmakers hit the road as COVID-19 subsides","url":"https://stock-news.laohu8.com/highlight/detail?id=2138116154","media":"Reuters","summary":"May 25 (Reuters) - Investment bankers' business of putting together mergers and acquisitions (M&A) h","content":"<p>May 25 (Reuters) - Investment bankers' business of putting together mergers and acquisitions (M&amp;A) has never been stronger. Neither has their fear of missing out on meeting clients.</p><p>Bankers are rushing to see company CEOs and other top executives in person as restrictions put in place to contain COVID-19 have eased. This is despite dealmaking through <a href=\"https://laohu8.com/S/ZM\">Zoom</a> meetings having flourished, with M&amp;A volumes in the first quarter of 2021 hitting a year-to-date record.</p><p>The total value of pending and completed deals rose 93% to $1.3 trillion during the quarter, the second-biggest quarter on record, according to Refinitiv data.</p><p>More than a dozen investment bankers interviewed by Reuters said they were worried they would lose clients if competitors cultivated them in person. Some fretted they could not expand their clientele without schmoozing in the flesh. Some also said they or their staff were fatigued from working long hours remotely.</p><p>\"People became Zoomed out. I was out visiting clients and they were very appreciative to have us back in front of them,\" said Drew Goldman, global head of investment banking coverage at Deutsche Bank   .</p><p>\"The meetings, frankly, were more productive than they would have been on a phone call or on video conference call,\" he said, adding that most clients are also tired of Zoom and happy to meet in person.</p><p>The U.S. Centers for Disease Control and Prevention said earlier this month that fully vaccinated people do not need to wear masks outdoors and can avoid wearing them indoors in most places.   This has made corporate executives more willing to engage in social activities, such as a round of golf and fine dining, that bankers organize to build rapport.</p><p>Rendezvous points have ranged from offices and restaurants to country clubs and backyards.</p><p>During negotiations of the megamerger between AT&amp;T's WarnerMedia    and Discovery   , bankers gathered in Discovery Chief Executive David Zaslav's New York City brownstone to hash out details of a deal that would create a company with an enterprise value of over $120 billion.</p><p>The pandemic's toll was the heaviest on young bankers who learn their trade and develop contacts by working alongside and traveling with senior colleagues, dealmakers said.</p><p>The social distancing restrictions made it challenging for them to evolve from footsoldiers to rainmakers, said <a href=\"https://laohu8.com/S/AONE\">one</a> junior banker, using a term for those who bring in new clients and revenue.</p><p>\"For younger bankers who are trying to make their way in the world, they're gonna have to be out there, pressing the flesh and meeting people,\" said Marc Cooper, chief executive of investment bank PJ Solomon.</p><p>There is no certainty that travel by bankers will reach pre-pandemic levels. While bankers are eager to travel for business development, many are less keen to spend time with clients on more procedural talks that can be carried out remotely and expect a hybrid model will persist.</p><p>\"Citi bankers are visiting clients when and where appropriate and safe,\" said Tyler Dickson, global co-head of banking, capital markets and advisory at $Citigroup Inc(C-N)$   . \"We do so on an as needed basis with the our firm's approval and clients' permission, while practicing safety measures such as social distancing and other relevant practices.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After M&A boom via Zoom, dealmakers hit the road as COVID-19 subsides</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter M&A boom via Zoom, dealmakers hit the road as COVID-19 subsides\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-25 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>May 25 (Reuters) - Investment bankers' business of putting together mergers and acquisitions (M&amp;A) has never been stronger. Neither has their fear of missing out on meeting clients.</p><p>Bankers are rushing to see company CEOs and other top executives in person as restrictions put in place to contain COVID-19 have eased. This is despite dealmaking through <a href=\"https://laohu8.com/S/ZM\">Zoom</a> meetings having flourished, with M&amp;A volumes in the first quarter of 2021 hitting a year-to-date record.</p><p>The total value of pending and completed deals rose 93% to $1.3 trillion during the quarter, the second-biggest quarter on record, according to Refinitiv data.</p><p>More than a dozen investment bankers interviewed by Reuters said they were worried they would lose clients if competitors cultivated them in person. Some fretted they could not expand their clientele without schmoozing in the flesh. Some also said they or their staff were fatigued from working long hours remotely.</p><p>\"People became Zoomed out. I was out visiting clients and they were very appreciative to have us back in front of them,\" said Drew Goldman, global head of investment banking coverage at Deutsche Bank   .</p><p>\"The meetings, frankly, were more productive than they would have been on a phone call or on video conference call,\" he said, adding that most clients are also tired of Zoom and happy to meet in person.</p><p>The U.S. Centers for Disease Control and Prevention said earlier this month that fully vaccinated people do not need to wear masks outdoors and can avoid wearing them indoors in most places.   This has made corporate executives more willing to engage in social activities, such as a round of golf and fine dining, that bankers organize to build rapport.</p><p>Rendezvous points have ranged from offices and restaurants to country clubs and backyards.</p><p>During negotiations of the megamerger between AT&amp;T's WarnerMedia    and Discovery   , bankers gathered in Discovery Chief Executive David Zaslav's New York City brownstone to hash out details of a deal that would create a company with an enterprise value of over $120 billion.</p><p>The pandemic's toll was the heaviest on young bankers who learn their trade and develop contacts by working alongside and traveling with senior colleagues, dealmakers said.</p><p>The social distancing restrictions made it challenging for them to evolve from footsoldiers to rainmakers, said <a href=\"https://laohu8.com/S/AONE\">one</a> junior banker, using a term for those who bring in new clients and revenue.</p><p>\"For younger bankers who are trying to make their way in the world, they're gonna have to be out there, pressing the flesh and meeting people,\" said Marc Cooper, chief executive of investment bank PJ Solomon.</p><p>There is no certainty that travel by bankers will reach pre-pandemic levels. While bankers are eager to travel for business development, many are less keen to spend time with clients on more procedural talks that can be carried out remotely and expect a hybrid model will persist.</p><p>\"Citi bankers are visiting clients when and where appropriate and safe,\" said Tyler Dickson, global co-head of banking, capital markets and advisory at $Citigroup Inc(C-N)$   . \"We do so on an as needed basis with the our firm's approval and clients' permission, while practicing safety measures such as social distancing and other relevant practices.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JPM":"摩根大通","MS":"摩根士丹利","BAC":"美国银行","WFC":"富国银行","GS":"高盛","C":"花旗"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138116154","content_text":"May 25 (Reuters) - Investment bankers' business of putting together mergers and acquisitions (M&A) has never been stronger. Neither has their fear of missing out on meeting clients.Bankers are rushing to see company CEOs and other top executives in person as restrictions put in place to contain COVID-19 have eased. This is despite dealmaking through Zoom meetings having flourished, with M&A volumes in the first quarter of 2021 hitting a year-to-date record.The total value of pending and completed deals rose 93% to $1.3 trillion during the quarter, the second-biggest quarter on record, according to Refinitiv data.More than a dozen investment bankers interviewed by Reuters said they were worried they would lose clients if competitors cultivated them in person. Some fretted they could not expand their clientele without schmoozing in the flesh. Some also said they or their staff were fatigued from working long hours remotely.\"People became Zoomed out. I was out visiting clients and they were very appreciative to have us back in front of them,\" said Drew Goldman, global head of investment banking coverage at Deutsche Bank   .\"The meetings, frankly, were more productive than they would have been on a phone call or on video conference call,\" he said, adding that most clients are also tired of Zoom and happy to meet in person.The U.S. Centers for Disease Control and Prevention said earlier this month that fully vaccinated people do not need to wear masks outdoors and can avoid wearing them indoors in most places.   This has made corporate executives more willing to engage in social activities, such as a round of golf and fine dining, that bankers organize to build rapport.Rendezvous points have ranged from offices and restaurants to country clubs and backyards.During negotiations of the megamerger between AT&T's WarnerMedia    and Discovery   , bankers gathered in Discovery Chief Executive David Zaslav's New York City brownstone to hash out details of a deal that would create a company with an enterprise value of over $120 billion.The pandemic's toll was the heaviest on young bankers who learn their trade and develop contacts by working alongside and traveling with senior colleagues, dealmakers said.The social distancing restrictions made it challenging for them to evolve from footsoldiers to rainmakers, said one junior banker, using a term for those who bring in new clients and revenue.\"For younger bankers who are trying to make their way in the world, they're gonna have to be out there, pressing the flesh and meeting people,\" said Marc Cooper, chief executive of investment bank PJ Solomon.There is no certainty that travel by bankers will reach pre-pandemic levels. While bankers are eager to travel for business development, many are less keen to spend time with clients on more procedural talks that can be carried out remotely and expect a hybrid model will persist.\"Citi bankers are visiting clients when and where appropriate and safe,\" said Tyler Dickson, global co-head of banking, capital markets and advisory at $Citigroup Inc(C-N)$   . \"We do so on an as needed basis with the our firm's approval and clients' permission, while practicing safety measures such as social distancing and other relevant practices.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":257,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}